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Abstract
This dissertation describes the development of elastomeric capture microparticles
(ECµPs) and their use with acoustophoresis to perform affinity capture assays. ECµPs
that function as negative acoustic contrast particles were developed by crosslinking
emulsion-based droplets composed of commercially available silicone precursors
followed by functionalization with avidin/biotin reagents. The size distribution of the
ECµPs was very broad or narrow depending on the emulsion system that was used during
the synthesis process. Elastomeric particles exhibited a very broad size distribution when
a bulk-emulsion process was used; however, when microfluidic systems were utilized,
their size distribution became comparatively narrow. The functionalization of elastomeric
particles was accomplished by the non-specific adsorption of avidin protein followed by
bovine serum albumin (BSA) blocking and bio-specific adsorption of a biotinylatedcapture antibody. Polydisperse ECµPs were functionalized to bind prostate specific
iv

antigen (PSA) or IgG-phycoerythrin (PE) in aqueous media (buffer, plasma, blood);
whereas monodisperse ECµPs were functionalized to bind a high density lipoprotein in
the aqueous media. Polydisperse ECµPs functionalized to bind PSA in a physiological
buffer (PBS pH 7.4) demonstrated nanomolar detection using flow cytometry analysis;
whereas ECµPs functionalized to bind IgG-PE demonstrated picomolar detection in 10%
porcine plasma. ECµPs have a specific density of ~1.03 and are more compressible than
their surrounding aqueous media; which allowed the ECµPs to exhibit negative acoustic
contrast properties under an ultrasonic acoustic standing wave field. The negative
acoustic contrast property of ECµPs was advantageously utilized in an IgG-PE assay
conducted in 0.1% whole porcine blood. The ligand-bound ECµPs suspended in the
diluted blood sample were flowed through an acoustofluidic device where the application
of an ultrasonic acoustic standing wave field focused the ligand-bound ECµPs to pressure
antinodes and the positive acoustic contrast blood cells to the central pressure node of the
microchannel. As a result of laminar flow, focused ligand-bound ECµPs and blood cells
were flowed into properly aligned outlet channels at the downstream trifurcation, where
they where collected separately off-chip. The cell-free fraction containing ligand-bound
ECµPs was analyzed using flow cytometry; where the detection of IgG-PE was in the
picomolar range. This approach has potential applications in the development of rapid
assays that detect the presence of low concentrations of biomarkers in a number of
biological sample types.
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Chapter 1 Introduction
Acoustofluidics
Microfluidics deals with the flow and manipulation of small amounts of liquids
and suspensions (e.g., microparticles) in channels with dimensions in the tens to hundreds
of micrometers.1 The small dimensions of the microchannels allow for the absence of
turbulent flow patterns and the appearance of laminar flow-based streamlines. Under such
a flow regime, laminar flow streamlines allow for predictable spatial and temporal
control over the flow of solutes and suspensions under the influence of an external field.2
The application of using microfluidics in conjunction with applied external fields allow
for the precise manipulation of particle suspensions and cells (e.g., concentrations,
separations, trapping) in microfluidic devices that can be advantageously used for
biomedical applications (e.g., cell sorting, and enrichment). Some of the commonly used
microfluidic-based manipulation methods are: magnetic,3 dielectrophoresis,4 optical
tweezers,5 inertia,6 and acoustophoresis.7 Some advantages for using microfluidic devices
in conjunction with external fields are: high-throughput capabilities, inexpensive to
fabricate, require low consumption of reagents and power, give rapid particle
manipulation times, and are generally portable for field usage.
Acoustofluidics is a subset of microfluidics that deals with the application of
mechanical sound waves in microfluidic environments;2 it is also generally used to
perform acoustophoresis.7 According to Thomas Laurell, acoustophoresis can simply be
defined as "migration with sound." Acoustophoresis performed using an acoustofluidic
device is a gentle, non-contact method to manipulate micro objects (e.g., cells,
microparticles) based on size, shape, density, and compressibility.7 Acoustophoresis has
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many biomedical and biotechnical applications such as: elimination of lipid emboli from
shed blood in thoracic surgery,8 blood component fractionation and particle sizing,9
contaminated blood plasma replacement and buffer media exchange,10 plasmapheresis11
and positioning and trapping of cells,12 and stream-line focusing of particles and cells for
flow cytometry analysis.13 Furthermore, acoustophoresis can easily be integrated with
magnetic separators,14 dielectrophoresis,4 and other automated systems.15
Acoustophoresis Theory
Acoustophoresis is generally based on an acoustic standing wave field that is
produced within the fluid-filled cavity of an acoustofluidic chip. Particles (or cells)
suspended in this fluid-filled cavity can experience a primary acoustic radiation force that
can be expressed with the following primary acoustic force equation (1)16 that was partly
derived from the work of Gor'gov et al.17

F! = −

πp! V! β!
φ β, ρ sin 2kx
2λ

φ β, ρ =

5ρ! − 2ρ! β!
− !!!!!!
2ρ! + ρ!
β!

(1)

(2)

The magnitude of the primary acoustic force (Fp) is directly proportional to the volume
of the particle (V! ), the pressure amplitude of the field (p! ), the applied frequency (1/λ),
and the acoustic contrast factor  φ β, ρ . The value of the acoustic contrast factor depends
on the density of the particle (ρ! ) and the surrounding media (ρ! ) and the

2

compressibility of the particle (β! ) and the surrounding media (β! ). If φ β, ρ   has a
positive value then the acoustic field will exert a time-averaged force moving the particle
to the acoustic pressure node of a standing wave (positive acoustic contrast particles).
However, if φ β, ρ   has a negative value then the acoustic field will exert a timeaveraged force moving the particle to acoustic pressure antinodes in a standing wave
(negative acoustic contrast particles). The acoustic forces exerted on particles (or cells)
are to a large extent independent of the ionic strength and pH of the surrounding medium,
or the surface charge of the particles.18 A more detailed description of the acoustic forces
exerted on particles under an acoustic standing wave field can be found in Bruus et al.19
In regards to this dissertation report, the most pertinent application of the
acoustophoretic theory is the binary separation of particles with different acoustic
contrast properties (negative and positive acoustic contrast). The concept of separating
particles with different acoustic contrast properties was originally patented by Kaduchak
et al. where they were able to demonstrate that hollow, compressible glass spheres
function as negative acoustic contrast particles and can be separated from positive
acoustic contrast particles.20 In their patent application they discussed methods (which
were never implemented or published) to use negative acoustic contrast capture particles
to capture protein biomarkers in biological solutions containing cells (positive acoustic
contrast particles) followed by acoustophoresis and on-chip spectroscopic analysis (e.g.,
on-chip flow cytometry).
Acoustofluidic devices have been fabricated using glass, steel, quartz, and siliconbased microfluidic devices. These microfluidic devices are easily converted into
acoustofluidic devices by coupling an actuating lead zirconate titanate piezoelectric
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transducer (PZT) ceramic to their surfaces. Coupling of an actuating (drive) PZT to the
surfaces of microfluidic devices can be performed by using cyanoacrylate glue or some
other type of super glue. PZTs are generally operated using a high power RF (radio
frequency) amplifier where the frequency is modulated using a waveform generator. The
operating frequencies of the actuating PZT is determined based on the thickness of the
actuating PZT crystal. Acoustofluidic devices are generally referred to as acoustic
"resonators." An acoustic resonator is an acoustofluidic device that naturally vibrates (or
oscillates) at specific frequencies called resonance frequencies. Vibration at these
resonance frequencies leads to the formation of an acoustic standing pressure wave
within the fluid-filled cavity of the microchannel. An acoustic resonator has natural
resonance frequencies that are dependent upon the width of its microchannel. The
fundamental resonance frequency (1st harmonic) of an acoustic resonator is the
frequency that allows half the wavelength (1/2λ) of the acoustic standing wave to fit
within the fluid-filled cavity of the microchannel; thus the fundamental resonance
frequency is 1/2λ, which gives 2 pressure antinodes at the side walls and a pressure node
at the center of the microchannel. Utilizing fractional harmonics (1/2λ, λ, 3/2λ, 4/2λ....)
the number of pressure nodes (pressure minima) and pressure antinodes (pressure
maxima) can be modulated with a PZT with the appropriate thickness.
The acoustic resonator that is most pertinent to this dissertation is fabricated from
silicon. Silicon has exceptional sound reflecting properties that minimize acoustic losses.
The minimization of acoustic losses during the reflection of the sound wave in a siliconbased acoustic resonator is due to the high characteristic acoustic impedances of the
silicon (~19.79 x 106 kg m-2s) compared to the fluid-filled cavity (water~1.49 x 106 kg m-
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s).18 Further, the high acoustic impendence of the actuated PZT (30.8 x 106 kg m-2s)

along with the acoustic impendences of the silicon material and the fluid-filled cavity
allow easy acoustic energy transfer from the PZT to the silicon material and then finally
into the fluid-filled cavity.18,22 These physical characteristics of silicon make it one of the
most common materials used for the fabrication of acoustofluidic devices.
Silicon acoustofluidic devices can be easily microfabricated using silicon wafers,
pre-established photolithography and deep reactive ion etching (DRIE); these methods
are explicitly discussed by Austin-Suthanthiraraj et al.22 These microfabricated processes
are versatile and allow silicon microchannels to be designed with a diversity of
microchannel patterns (e.g., straight channels, bifurcations, trifurcations) with precise
spatial control of microchannel dimensions (e.g., depth, width, and length). Further, the
use of DRIE as a method to etch silicon microchannels allows rectangular microchannels
to be microfabricated with straight vertical side walls that contribute to the longitudinal
sound wave reflecting properties of silicon-based acoustofluidic devices. Once the
microchannels have been etched into the silicon, a transparent Pyrex® glass slide is
anodically bonded onto the silicon etched microchannels.22 Sealing the silicon
microchannels with a transparent glass slide allows visual observation of acoustophoresis
using microscopy and imaging technologies; this observation can aide in the optimization
and fine tuning of the acoustic standing wave within the microchannel. The versatility in
how silicon acoustofluidic microchannels are designed and microfabricated can allow
silicon acoustofluidic devices to be developed for a diversity of biomedical and
biotechnology applications that utilize acoustophoresis, such as: 1-dimensional focusing
for low-cost flow cytometry,22 acoustic trapping,12 continuous washing of cells and assay
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particles,10 and a binary separation system for particles with different acoustic contrast
properties.8
The microfabricated silicon acoustofluidic device utilizes a rectangular
microchannel along with an actuating PZT to perform acoustophoresis. To prevent visual
interference of acoustophoresis using microscopy, the PZT can be attached to the bottom
of the device (Figure 1.1); although the PZT can be effectively used for acoustophoresis
when attached to the bottom, side, or on top of the glass slide.10 The actuation of the PZT
at the appropriate resonance frequency (1/2λ) generates a 1-dimensional, longitudinal
acoustic standing wave within the silicon microchannel. The generation of this acoustic
standing wave at 1/2λ exerts a time-averaged acoustic radiation force that positions
positive acoustic contrast particles (e.g., cells) at the central pressure node, and negative
acoustic contrast particles (e.g., lipids) at the pressure antinodes at the side walls of the
microchannel (Figure 1.1).
Acoustofluidic Assays
Many bioassay systems (e.g., Enzyme-Linked Immunosorbent Assay: ELISA, and
mass spectrometry-based assays) performed in biological samples, e.g., plasma or sera,
necessitate removal of blood cells and dilution of plasma (e.g., 1000 fold) prior to
performing the assay. In the case of biomarker (e.g., PSA) detection and quantification in
human plasma using ELISA or mass spectrometry, removal of blood cells is necessary as
they are typically present at very high concentrations (5x109 cells per mL) so that they
represent a large source of background "noise" relative to the biomarker "signal" of
interest.23 Removal of background generating blood cells therefore increases signal-to-

6

noise (S/N ratio) to improve accuracy, sensitivity, limit-of-detection (LOD), and
reproducibility of the assay system.
Centrifugation is the most common method for blood cell removal, but can be
problematic. Centrifugation can often be time consuming (10-20 minutes); damaging to
cells -leaving behind large amounts of cellular debris in plasma; often requires large
volumes of blood (2.5-10 mL); and is generally not very portable for field usage.
The use of a silicon-based acoustofluidic device for obtaining cell-free plasma has several
advantages over centrifugation, such as it 1) allows the usage of small volumes
(microliters) of whole or diluted blood; 2) is a rapid (seconds), non-contact method for
separation that does not damage (i.e., lysis) blood cells; and 3) can be performed in a
portable, silicon-based acoustofluidic device.

Figure 1.1 Cross-section of a silicon-based acoustofluidic device with the positive
acoustic contrast particles (black) focused at the pressure node and the negative acoustic
contrast particles (white) focused at the pressure antinodes under an acoustic standing
wave field.
7

Although the use of a silicon-based acoustofluidic device for obtaining cell-free plasma
has advantages over centrifugation, the use of common analysis techniques such as
ELISA or mass spectrometry still requires multiple additional processing steps to enable
accurate and sensitive analysis. Cell-free plasma protein assays performed using ELISA
requires an initial dilution (e.g., 1000-fold) followed by multiple washing steps to obtain
accurate and sensitive analysis; whereas mass spectrometry often requires dilution
followed multiple protein purification steps (e.g., 2-D gel electrophoresis,
chromatography, filtration methods, trypsin digestion) prior to analysis. To obviate these
excessive processing steps, capture particles can be designed that will be able to 1)
capture a plasma protein biomarker present in an undiluted or minimally diluted blood
sample; 2) have negative acoustic contrast properties that allow separation from
background generating blood cells (positive acoustic contrast particles) in an applied
acoustic standing wave field and 3) can produce a fluorescence signal quantitatively
proportional to the amount of captured protein which is immediately measurable in a
flow cytometer without prior washing steps (Figure 1.2).
The ability to perform the biospecific capturing of a biomarker-analyte (e.g.,
PSA) in a whole blood sample without dilution (or with minimal dilution) has potential to
enhance detection and quantification of biomarkers (PSA) that are present at low
concentration levels (e.g., picomolar, femtomolar). Once negative acoustic contrast
capture particles have bound the desired biomarkers, the removal of high quantities of
blood cells using acoustophoresis becomes crucial for accurate flow cytometry analysis
of ligand-bound capture particles; as large quantities of blood cells can overwhelm the
electronic systems of most flow cytometers (e.g., Accuri C6).
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Figure 1.2 Schematic diagram outlining the proposed bioassay strategy for using
acoustophoresis as a method to separate biomarker (black)-bound elastomeric capture
microparticles (blue) from blood cells (red) prior to performing flow cytometry analysis
without prior washing steps.

9

Particle Design
One of the core objectives of this project is to synthesize negative acoustic
contrast particles that can be separated from positive acoustic contrast particles (e.g.,
cells) using acoustophoresis. To achieve this objective, a material that possesses a
negative acoustic contrast value for the acoustic contrast factor (equation 2) must be used
to synthesize negative acoustic contrast particles. To function as a negative contrast
particle, the material must have a compressibility and density that allow

𝟓𝝆𝒑 !𝟐𝝆𝒐
𝟐𝝆𝒑 !𝝆𝒐

𝜷

   <    𝜷𝒑 ;
𝒐

when this is the case the acoustic contrast factor exhibits a negative value and the
synthesized particles function as negative contrast particles. However, if the opposite
occurs, if

𝟓𝝆𝒑 !  𝟐𝝆𝒐
𝟐𝝆𝒑   !  𝝆𝒐

𝜷

   >    𝜷𝒑 , then the acoustic contrast factor value is positive and the
𝒐

synthesized particles function as positive contrast particles.
To simplify the design of negative contrast particles, if the densities of the
material and their surrounding medium display negligible differences, then the acoustic
𝜷

contrast factor formula can be simplified into 1 −    𝜷𝒑 ; thus the value of the acoustic
𝒐

contrast factor becomes exclusively dependent upon the compressibility ratio of the
suspended particles and their surrounding medium. Under such a circumstance, if
𝛽! >    𝛽! , then the acoustic contrast factor value is negative and the synthesized particles
function as negative contrast particles; however, if 𝛽! <    𝛽! , then the acoustic contrast
factor value is positive and the particles function as positive contrast particles.
This simplification of the acoustic contrast formula gives insight into the type of
material needed to produce a negative contrast particle. Sylgard 184 is a type of
polydimethylsiloxane (PDMS) that can be crosslinked into a compressible rubber-like
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material. The compressibility of the Sylgard 184 can be modulated based on the amount
of crosslinking agent added to the prepolymer prior to the curing process (also referred to
as crosslinking process); which forms a crosslinked Sylgard 184 elastomer. The less
crosslinking agent added to the prepolymer, the more compressible will be the resulting
particle and the more likely that it will have negative acoustic contrast properties. The
conventional 10:1 ratio of Sylgard 184 prepolymer to crosslinking agent results in a
particle that is more compressible than water. Sylgard 184 particles also have a specific
gravity of 1.03 and are therefore approximately the same density as water
(𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝑔𝑟𝑎𝑣𝑖𝑡𝑦   =   

!"#$%&'  !"  !"#$%&'  !"#
!"#$%&'  !"  !"#$%

). This indicates that compressibility will be

the major factor determining acoustic contrast and that conventionally crosslinked
Sylgard 184 particles will have negative acoustic contrast properties in aqueous media.
The specific gravity of Sylgard 184 particles has an additional advantage in that the
particles will tend to remain in suspension in aqueous media such as PBS. This will
facilitate flow cytometry analysis in which particle suspension is required.
The significant portion of research presented in this dissertation relates to the
synthesis of negative contrast particles using Sylgard 184; however, other compressible,
water-insoluble elastomeric materials may possess negative acoustic contrast properties
that can be modulated based on addition of crosslinking reagents, such as: other silicones,
natural rubbers, polyurethanes, butyl rubbers, polybutadienes, styrene butadienes,
fluoroelastomers, polyether block amides, ethylene-vinyl acetates, polyacrylic rubbers,
and many others...etc.
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Chapter 2 Goals and Specific Aims
A core objective of this dissertation is to synthesize a particle that functions as a
negative acoustic contrast capture particle under an acoustic standing wave. Negative
acoustic contrast particles can be used in blood-based assays (or other types of biological
assays) where biomarker-bound negative acoustic contrast particles are continuously
separated from blood cells using a silicon-based acoustofluidic device with a downstream
trifurcation. Once biomarker-bound negative acoustic contrast particles are collected,
without high concentration levels of blood cells, they can be accurately analyzed using
flow cytometry. We hypothesize that 1) elastomeric capture microparticles (ECµPs) will
function as negative acoustic contrast particles; and 2) can be used in bioassays in which
they can be rapidly separated and collected from blood cells prior to flow cytometry
analysis using a silicon-based acoustofluidic device. Four specific aims must be
accomplished to complete development of this system.
1) Develop a protocol for the synthesis of elastomeric particles.
2) Develop a method to functionalize elastomeric particles to serve as platforms
for affinity capture bioassays.
3) Demonstrate that functionalized elastomeric particles function as negative
acoustic contrast particles and can be acoustically separated from blood cells
using a silicon-based acoustofluidic device.
4) Demonstrate the use of ECµPs in the capturing of a biomarker in a blood
sample, followed by acoustophoresis and subsequent flow cytometry analysis.
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Chapter 3 Synthesis of Elastomeric Particles
Polydimethylsiloxane (PDMS)
Polydimethylsiloxane (PDMS) is a rubber-like material that belongs to an
organosilicon group referred to as silicones.1 Synthesized silicone is composed of an
alternating sequence of silicon and oxygen atoms that constitute the basic structure and
backbone of the silicone polymer (Figure 3.1).2 The silicon atoms in PDMS are bonded to
organic groups (Me: -CH3). The presence of organic groups (methyl groups) and an
inorganic backbone (-Si-O-Si-) give PDMS unique physical and chemical properties (e.g.,
optically transparent, inert, non-toxic, and non-flammable) that allow them to function as
fluids, emulsions, compounds (e.g., silicone surfactants), resins, contact lenses, medical
devices and elastomers, food, caulking, and lubricating oils.2

Figure 3.1 Chemical structure of the PDMS prepolymer composed of organic groups (CH3) and an inorganic backbone (-Si-O-Si-).1

15

Silicone precursors can be polymerized into PDMS prepolymers with different
chain lengths.2 Increased polymerization results in an increased number of PDMS
monomers being incorporated into the PDMS prepolymers;2 thus the molecular weight of
the PDMS prepolymers is controlled based on the degree of polymerization. As the
molecular weight of the PDMS prepolymers increases, the viscosity of the PDMS
prepolymer also becomes greater.2 According to Dow Corning, their PDMS fluids range
in kinematic viscosity from 0.65 cSt to 20,000,000 cSt -which is thicker than chewing
gum. In regards to this dissertation report, the type of PDMS that is predominantly used
is Sylgard 184; which has a molecular weight of 20,000 g/mole3 and on average 270
dimethylsiloxane repeat units;4 corresponding to a kinematic viscosity of 5000 cSt.5 The
synthesized PDMS prepolymers come in the form of loosely entangled prepolymers that
can be crosslinked to form a compressible, water-insoluble elastomer. The crosslinking of
PDMS prepolymers into a 3-dimensional polymeric network, consists of forming
chemical bonds (or links) between individual PDMS prepolymers.6
Sylgard 184 is a heat curable type of PDMS that comes commercially from Dow
Corning® as a kit composed of two separated parts (parts A and B) in which part (A),
with a viscosity of 5000 cSt, is composed of siloxane prepolymers with reactive terminal
vinyl groups (base), along with a platinum catalyst, and the second part (B), with a
viscosity of 100 cSt, is composed of siloxane prepolymers with silicon-hydride groups
(curing agent: or referred to as crosslinking agent). When siloxane (A) and (B) are mixed
together, in the presence of the platinum-based catalyst, an addition of the Si-H (silicon
hydride) across the double bonds (vinyl groups) forms -(Si-CH2-CH2-Si)- linkages (or
crosslinks);7 this method is commonly referred to as hydrosilylation of the double bonds
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(Figure 3.2), or more generically referred to as cross-linking.4 These cross-links will thus
convert the liquid-like properties of the PDMS prepolymers into a more dense
crosslinked polymeric network that now contains rubber-like elastic (or compressible)
properties.

Figure 3.2 The crosslinking in the formation of the PDMS elastomer involving the
reaction of vinyl end-capped siloxane oligomers and the dimethylmethylhydrogen
siloxane cross-linker by hydrosilylation with a platinum catalyst.4
When PDMS is not crosslinked, the siloxane polymers exist is a loosely entangled
configuration, giving PDMS a high viscoelasticity, i.e., exhibiting both viscous and
elastic characteristics when undergoing deformation. Upon crosslinking, using the abovementioned mechanism (Figure 2.2), PDMS becomes stiffer, with less compressibility,
depending on the concentration of curing agent (crosslinking agent) incorporated in the
crosslinking procedure; thus the degree of stiffness and compressibility can be manually
controlled by altering the base to crosslinking agent ratio. The shear modulus G
(~measurement of a material's stiffness) of PDMS may vary from 100 kPa to 3 MPa
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depending of the preparation conditions (e.g., monomer ratios during synthesis, amount
of crosslinking agent).8
PDMS, along with all silicones, are relatively stable as a result of the strong polar
covalent bonds that exist between the silicon and oxygen atoms of the siloxane backbone;
the bond energies of these polar covalent bonds are on the order of 452 kJ/mol.1 PDMS is
also characterized with a surface tension that is within the biocompatible range for
elastomers (20-30 mN/m).1 PDMS also adopts a structural configuration that exposes the
methyl groups (organic groups) to the surrounding environment. The surface tension of
PDMS along with its hydrophobic surface (organic surface), make PDMS a stable
biocompatible polymer. It must also be noted that these physical properties of PDMS are
virtually unaffected by the crosslinking process; and thus PDMS remains a stable
biocompatible polymer rather it is crosslinked or not.
PDMS is a water-insoluble elastomer with unique physical properties that make it
ideal for conversion into negative acoustic contrast particles. PDMS is relatively low-cost,
chemically inert, compatible with biological cells, permeable to gases and selective
agents, optically transparent, and has a broad shear modulus or compressibility that can
be modulated based on preparation conditions.9,10 As a result of this, we pursued
emulsion-based methods to synthesize polydisperse and monodisperse elastomeric
particles; with the intention of using them as negative acoustic contrast particles for
affinity capture assays with flow cytometry. Emulsion systems are well established and
have predetermined protocols and systems, e.g., bulk11 and microfluidic systems,4,5 that
have worked well in previously published reports. Herein we synthesized elastomeric
negative acoustic contrast particles out of PDMS-based materials using emulsion systems.
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In the preceding section we describe emulsion science and give in-depth background
information on the bulk and microfluidic methods that are used to synthesize elastomeric
negative acoustic contrast particles.
Emulsion Science
An emulsion is a mixture of two or more immiscible liquids where one phase, the
dispersed phase, is dispersed in another phase referred to as the continuous phase.12,13
The dispersed phase (e.g., oil), in order to adopt the most stable energetic configuration,12
usually forms spherical liquid droplets, i.e., also referred to as suspended liquid colloids,
that are randomly distributed within the continuous phase (e.g., water). Some common
examples of emulsions are, vinaigrettes, milk, and mayonnaise.
At constant volume and temperature, the formation of an emulsion is governed by
the Gibb's free energy of the isolated system.14 The Gibb's free energy can be described
by the following equation:

∆𝑮𝒇𝒐𝒓𝒎 =   𝜸∆𝑨 −   𝑻∆𝑺𝒎                       (𝟏)

The value of Gibb's free energy is determined based on the interfacial tension (γ); the
change in interfacial area (ΔA); the temperature (T); and the change in entropy (ΔSm)
upon emulsification (mixing). Generally in most cases, immiscible liquids in contact
with each other generate a high interfacial tension that becomes significantly larger than
the entropic contribution (𝛾∆𝐴 >> 𝑇∆𝑆 ! ). As a result of this high interfacial tension, the
formation of most emulsions are not thermodynamically spontaneous (Δ𝐺!"#$ >>   0),
and therefore require the input of large amounts of energy, usually in the form of shear
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forces generated by homogenization, to form an emulsion. This input of energy therefore
increases the entropic contribution (𝛾∆𝐴 ≤   𝑇∆𝑆 ! ) and allows an emulsion to form
(∆𝐺!"#$ ≤   0). To decrease the amount of input energy that is needed to form an
emulsion, surfactants can be used to lower the interfacial tension.14
Surfactants can be defined as surface active agents (e.g., detergents, polymeric
surfactants, proteins) that have amphiphilic properties, i.e., hydrophilic and hydrophobic
components,15 which reduce the interfacial tension between the suspended liquid colloids
and the continuous phase (Figure 3.3).16

Figure 3.3 Image of a generic amphiphilic surfactant that is composed of a negatively
charged hydrophilic head group and a hydrophobic tail group.
The addition of surfactant not only reduces the interfacial tension between the two
phases, but increases the kinetic stability of the dispersed liquid phase; thus minimizing
aggregation (also referred to as flocculation) and coalescence.16 This kinetic stability is a
consequence of the electrostatic charge or steric barrier that is provided by the adsorbed
surfactants to the interface of the dispersed droplets.
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Generally, surfactants that are used in the stabilization of emulsions come in the
form of detergents. Detergents have an exceptional ability to solubilize biomolecules and
are often used in the washing of planar and micro-bead surfaces that are used as
platforms for assays (e.g., enzyme linked immunosorbent assays: ELISA). It is important
to note that all detergents are considered surfactants, but not all surfactants are considered
detergents. Though most emulsion stabilizing surfactants come in the form of detergents,
there are also examples of proteins (e.g., casein)15 which have been used to stabilize oilin-water emulsions. Emulsions produced in the presence of surfactants have many
applications, such as in the preparation of foods, agrochemicals, pharmaceuticals, paints,
cosmetics, oil industries, and sunblock, and many others.
Many types of emulsions exist, but the two most common types of emulsions are
water-in-oil and oil-in-water. Whether an emulsion of oil and water turns into a water-inoil emulsion or an oil-in-water emulsion depends on the volume fraction12 of both phases
and the type of surfactant present.17 Generally surfactants tend to promote the dispersion
of the phase in which they do not dissolve very well. A simple example of a water-in-oil
emulsion would be water droplets dispersed in a continuous mineral oil phase containing
a silicone-based polymeric surfactant named Cetyl PEG/PPG-10/1 Dimethicone (ABIL
EM 90). A water-in-oil emulsion results because the ABIL EM 90 surfactant is more
soluble in the oil phase than the water phase, and because the volume fraction of the oil
phase is significantly larger than the volume fraction of the water phase. However, if you
intended to form an oil-in-water emulsion you could adjust the volume fraction of both
phases and use a surfactant that was more soluble in the water phase (e.g., Pluronic® F108) than the oil phase. This observation has been coined as the Bancroft rule - "The
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phase in which an emulsifier (surfactant) is more soluble constitutes the continuous
phase."17
Some surfactants that are commonly used to form water-in-oil emulsions are:
sorbitan stearate, polyglyceryl oleate, lecithin, sorbitan monooleate, glyceryl monooleate,
lanolin, and lanolin alcohols. Surfactants commonly used for oil-in-water emulsions are:
cetyltrimethylammonium bromide (CTAB), sodium dodecyl sulfate (SDS), poly(ethylene
glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Pluronic® F-108),
and other water-soluble surfactants .
More important in regards to this dissertation report are bulk oil-in-water
emulsions. Bulk oil-in-water emulsion systems are generally used to produce large
quantities of polydisperse oil droplets in a relatively short period of time. Bulk oil-inwater emulsions are generally produced by depositing an oil in an aqueous phase
containing a water-soluble surfactant (e.g., Pluronic F108) followed by emulsification
using a hand-held homogenizer (Figure 3.4).18 The resulting emulsion forms polydisperse
(many-sizes) oil droplets that are kinetically-stabilized by the adsorbed surfactants at the
surface of the droplets.16 This bulk emulsification process using the hand-held
homogenizer always leads to polydisperse droplet formation. This polydispersity results
because the stresses and shear forces that are used to form droplets are not evenly
distributed throughout the entire system.19

22

Figure 3.4 Schematic depiction of a bulk oil-in-water emulsion being formed, in the
presence of a water-soluble surfactant, by the use of high energy emulsification using a
hand-held, commercially-available homogenizer.
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Monodisperse (same-size) droplets and particles have potential to be used for
exchange resins, spacers, calibration standards, and carriers or drugs, nutrition,
pharmaceutical, and cosmetics agents.20 In order for droplets (or particles) to function
properly and provide accurate and reproducible results, they must be prepared in a
monodisperse fashion. To make monodisperse emulsions, droplet-based microfluidic
systems can be utilized.19 Droplet-based microfluidic systems are generally characterized
by a low Reynold's number (𝑅𝑒 << 1)21 and extreme laminar flow regimes;22 these
extreme laminar flow regimes allow frictional or viscous forces to dominate inertial
forces.23 Microfluidic systems with extreme laminar flow regimes allow precise control
over the emulsification and thus control of the volumes and sizes of the generated
droplets.19
Some of the parameters that help determine the size of the produced droplets
using microfluidic systems are the flow rates of the continuous and dispersed phases, the
viscosities of the continuous and dispersed phases, the use of surfactants, the
hydrophobicity and hydrophilicity of the microchannel walls, and the size of the junction
(or orifice) where the two phases initially form an interface.21,22 According to David
Weitz at Harvard University, "...the use of microfluidic systems to form droplets, allows
each droplet to be formed individually, i.e., one droplet at a time - it is this property that
allows droplets to be formed in a very monodisperse fashion".
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The dimensionless capillary number (Ca) plays an important role in predicting
droplet breakoff within a microfluidic device.22 The capillary number (Ca) can be defined
as:

𝑪𝒂 =   

𝜼𝒗
                            (𝟐)
𝜸

The value of the capillary number is determined based on the viscosity of the continuous
phase (𝜂); the velocity of the continuous phase (𝑣); and the interfacial tension between
the oil and water phases (𝛾). Generally, droplet breakoff occurs above a critical value,
(𝐶𝑎);22 however , it has been reported in literature that (𝐶𝑎) can vary depending on the
geometry of the microfluidic microchannels.24 Spherical droplets usually form at Ca < 1,
where interfacial tension dominates viscous forces; and deformed and asymmetric
droplets generally form at Ca >> 1.21
The most common type of microfluidic devices for monodisperse droplet
generation are the polydimethysiloxane (PDMS) based microfluidic devices. The
fabrication of PDMS based microfluidic devices using soft-photolithographic methods
was pioneered by George Whitesides et al., at Harvard University.25 The benefits of using
PDMS based microfluidic devices are that they are relatively inexpensive, moldable,25
easy to fabricate compared to other microfluidic devices (e.g., silicon, glass), allow
reproducible results, and can be produced in microfluidic systems that generate 10,000
monodisperse droplets per second.19
The most common configurations used for monodisperse droplet generation in
PDMS microfluidic devices are the T-junction27 and flow focusing configurations.22,26,27
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In a T-Junction microfluidic device, the dispersed phase flows perpendicular to the
continuous phase in the main channel. (Figure 3.5) As a result of the pressure gradient,
the two phases are forced to flow into the orifice (or junction) where they form an
interface. As the dispersed phase flows through the orifice and down the main channel
the asymmetrical shear forces of the continuous phase, and the pressure gradient, cause
the tip of the dispersed phase to elongate and the neck of the dispersed phase to focus
until pinching off to form a dispersed droplet. In a flow focusing configuration, the
process of droplet formation is different in that the continuous phase is infused from the
side channels and thus the dispersed phase is exposed to symmetrical (not asymmetrical
as in the T-junction) shear forces. (Figure 3.6) These symmetrical shear forces cause the
tip of the dispersed phase to elongate and the neck of the dispersed phase to focus until
pinching off to form a droplet. The application of symmetrical shearing of the dispersed
phase by the continuous phase gives extreme control over droplet size and is therefore
capable of producing extremely uniform populations of droplets.
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Figure 3.5 Droplet formation in a T-junction. The dispersed phase and continuous phase
meet in a T-shaped junction perpendicularly. (Wd: 50 µm; Wc: 100 µm).21

Figure 3.6 Droplet formation in flow focusing device (FFD). The widths of the inlets of
dispersed phase and continuous phase, as well as the orifice are indicated as Wd, Wc and
Wo, respectively (Wd = Wc =200 µm: Wo = 50 µm).21

27

In this dissertation chapter we describe the synthesis of PDMS-based elastomeric
particles from two varieties of PDMS, Sylgard 184 (specific gravity ~ 1.03) and a low
molecular weight PDMS (specific gravity ~ 0.97) elastomer, using emulsion-based
synthesis strategies. We demonstrate that PDMS-based elastomeric particles can be
synthesized in a polydisperse or monodisperse fashion using modified bulk-emulsion
processes or PDMS-based microfluidic systems (flow focusing and T-junction
configurations) in the presence or absence of surfactant. We also demonstrate that
polydisperse elastomeric particles made in the absence of stabilizing surfactant
(detergent) can be stabilized towards aggregation using protein as a stabilizing surfactant
(avidin and bovine serum albumin: BSA) at the surface of elastomeric particles.
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Materials and Methods
Synthesis of polydisperse elastomeric particles
Sylgard 184 (specific gravity ~ 1.03) (1 g, at 10:2 ratio of PDMS prepolymer to
crosslinking agent) or low viscosity PDMS (specific gravity ~ 0.97) (1 g, at 9:1, 7:3, 5:5,
2.5:7.5, and 1.5:8.5 ratios of PDMS prepolymer to crosslinking agent) (Dow Corning
Corp., Midland, MI) were emulsified in 10 mL of ultrapure water (18.2 MΩ•cm @ 25 °C;
Synergy®, EMD Millipore) in the presence or absence of specific detergents (CTAB,
Tween 20), using a homogenizer (Power Gen 125, Fisher Scientific) set at 6K RPM for ~
60 seconds. The elastomeric droplets, with crosslinking agent, were cured at 100 °C for ~
1 hour to form crosslinked elastomeric particles. Elastomeric particles were imaged using
bright field microscopy (BH-2, Olympus) and a 4300 cool pix camera (Nikon). The scale
bar was calibrated based on standardized monodisperse particles (mean = 30.1 µm;
standard deviation = ± 2.1 µm; and a coefficient of variation = 6.6%) (Thermo Scientific).
Synthesis of monodisperse elastomeric particles
Sylgard 184
Sylgard 184 was used to form elastomeric microparticles using a T-junction
microfluidic chip (polydimethylsiloxane-based). The continuous phase contained
ultrapure water without the presence of stabilizing surfactant or with 1 µM of avidin
protein (Molecular Probes, Eugene, Oregon). To prevent Sylgard 184 (with crosslinking
agent) from wetting the micro-channel walls, the continuous phase was first injected
using a syringe pump (Nexus 3000, Chemyx Inc. Stafford, TX) at a flow rate of 5-13
µL/min. The dispersed phase, Sylgard 184 at 10:2 (kinematic viscosity~ 2209 cSt) or 6:4
(viscosity~ 827 cSt) ratio of PDMS prepolymer to crosslinking agent, was then injected
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into the microfluidic chip at a flow rate of 0.08-0.67 µL/min. Droplets were collected and
cured at 70 °C overnight to form crosslinked monodisperse elastomeric microparticles. A
Coulter counter (Z2 Coulter Particle Count and Size Analyzer, Becton Dickinson,
Franklin Lakes, NJ) was used to determine the size distribution of the near-monodisperse
elastomeric particles.
Low molecular weight PDMS
Low viscosity PDMS was used to form microparticles using a T-junction or flow
focusing microfluidic device (polydimethylsiloxane-based). The continuous phase
contained ultrapure water with the presence of stabilizing surfactants, CTAB (Millipore,
Billerica, MA), SDS (Bio-Rad, Hercules, CA), and Pluronic F108 (Sigma-Aldrich).
To prevent PDMS (with crosslinking agent) from wetting the micro-channel walls, the
continuous phase was first injected using a syringe pump (Nexus 3000, Chemyx Inc.
Stafford, TX) at a flow rate of 5 µL/min. The dispersed phase, low viscosity PDMS at 1:1
ratio (viscosity~ 450 cSt) of PDMS prepolymer to crosslinking agent, was then injected
into the microfluidic chip at a flow rate of 0.08 µL/min. Droplets were collected and
cured at 70 °C overnight to form crosslinked monodisperse elastomeric microparticles.
Stability Studies on Elastomeric Particles (Sylgard 184)
Time-dependent Studies
The synthesized polydisperse elastomeric particles (10:2 ratio of Sylgard 184
prepolymer to crosslinking agent) were incubated in glass scintillation vials with 10 mL
of ultrapure water with 0.1% bovine serum albumin (BSA). To determine the extent of
aggregation over time, elastomeric particles were imaged over a 1-week interval (days
1,2,3, and 7). The negative control was treated the same except incubation was performed

30

in ultra water without BSA protein.
Polydisperse elastomeric particles were functionalized by being incubated in 1µM
avidin in 1X PBS. Avidinylated-elastomeric particles (~1 x 106 particles/mL) were
subsequently incubated in a polypropylene microcentrifuge tube (Sorenson Bioscience,
Inc, Salt Lake City, Utah) with 1 mL of 1X PBS with 0.1% of BSA. To ensure
continuous suspension of elastomeric particles, the microcentrifuge tube was
continuously rotated at room temperature using a RotoFlex rotator (Argos Technologies,
Elgin, IL). The concentration of elastomeric particles was measured over time (days
0,2,4,6,9) using a flow cytometer (Accuri® C6).
Centrifugation and resuspension studies
Avidinylated-elastomeric particles (7.0 x 106 particle/mL) in washing buffer (1X
PBS with 0.1% BSA) were centrifuged for 2 minutes at 2900 x gravity. Upon careful
removal of supernatant, pelleted elastomeric particles were resuspended in 1 mL of the
washing buffer. After elastomeric particles were resuspended, flow cytometry (Accuri®
C6) measurements were performed to determine particle concentrations and forward
scatter. A total of 7-8 sequential centrifugal washes were performed where microparticles
were resuspended with the washing buffer prior to flow cytometry analysis.
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Results
Synthesis of Polydisperse Elastomeric Particles (Sylgard 184)
Polydisperse elastomeric microparticles were successfully synthesized using
Sylgard 184 (10:2 ratio of prepolymer to crosslinking agent) and a bulk oil-in-water
emulsion process in the absence of surfactant (Figure 3.7A). To verify the conversion of
elastomeric droplets into microparticles, elastomeric microparticles were dried on a glass
microslide (Figure 3.7B). The elastomeric microparticles demonstrated no observable
coalescence upon drying on the glass microslide; thus demonstrating successful
conversion of droplets into crosslinked microparticles.
Stability Studies on Elastomeric Particles (Sylgard 184)
Time-dependent Studies
Polydisperse elastomeric microparticles (Sylgard 184 at 10:2 ratio of prepolymer
to crosslinking agent) incubated in a protein-rich solution (ultra-pure water with 0.1%
BSA) over a week (days 1,2,3, and 7), demonstrated stability in regards to forming
particle aggregates (Figure 3.8). At the end of the week (day 7), elastomeric
microparticles incubated in the protein-rich solution, demonstrated a high degree of
turbidity, indicative of a solution containing few particle aggregates and a high
concentration of suspended microparticles. To determine the effects of the protein-rich
solution on the elastomeric particle stability, a control was performed in which
elastomeric microparticles were incubated in an ultra-pure water solution without protein
(Figure 3.8). Elastomeric microparticles incubated in ultra-pure water in the absence of
protein, formed particle aggregates within the first few hours after being synthesized; on
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(A)

(B)

Figure 3.7 Polydisperse elastomeric particles (Sylgard 184: specific gravity~1.03)
synthesized using a bulk-emulsion process without surfactant. (A) Bright field image of
polydisperse elastomeric particles being suspended in an aqueous solution. (B)
Polydisperse elastomeric particles dried on a glass slide. Note: Red bar equals ~ 100 µm.
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Figure 3.8 Protein (Bovine Serum Albumin: BSA) functions as a stabilizing surfactant
for elastomeric particles (Sylgard 184) synthesized in the absence of surfactant.
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day 7, the solution demonstrated a high degree of transparency in which a significant
amount of microparticles were aggregated and less remained suspended in solution.
These results demonstrate that protein can be successfully used as a stabilizing surfactant
for elastomeric microparticles.
Suspended avidinylated-elastomeric particles (1 x 106 particles/mL) demonstrated
stability in regards to particle aggregation in a protein-rich solution (1X PBS with 0.1
BSA) over a 9 day period where particle concentrations were measured using flow
cytometry. During the 9 day incubation period, the avidinylated-elastomeric particle
concentration hovered around 1 x 106 particles/mL; thus indicating that particle
aggregation was being minimized (Figure 3.9). These results demonstrate that suspended
avidinylated-elastomeric particles are stable enough to be used as capture particles in
protein-rich solutions (e.g., solutions containing high concentrations of albumins-plasma)
without significant aggregation occurring over extensive time periods.
Centrifugation and Resuspension Studies
Centrifugal washes (2900 x gravity @ 2 minutes) performed in a protein-rich
solution (1X PBS with 0.1% BSA) resulted in a decrease in the concentration of
avidinylated-elastomeric particles (Figure 3.10). The initial concentration of avidinylatedelastomeric particles in 1 mL of the protein-rich solution was ~ 7 x 106 particles/mL;
following 1 wash the concentration decreased to ~ 5.7 x 106 particles/mL; following the
2nd wash the concentration fell to ~ 4.3 x 106 particles/mL; and by the 8th wash the
particle concentration was ~ 1.3 x 106 particles/mL. Visual observation of the
supernatants under the microscope indicated that there were significant amounts of
particles remaining in the supernatants after centrifugal washes.
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Figure 3.9 Polydisperse avidinylated-elastomeric particles (Sylgard 184) demonstrate
stability overtime when suspended a protein-rich buffer (1X PBS with 0.1% BSA).
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Figure 3.10 Polydisperse avidinylated-elastomeric particles (Sylgard 184) in 1X PBS
(with 0.1% BSA) are lost during centrifugal washes (2900 x gravity @ 2 minutes) in
polypropylene centrifuge tubes.
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The significant particle losses during centrifugal washes could be explained by the
density of Sylgard 184 (specific gravity ~

!"#$%&'  !"  !"#$%&'  !"#
!"#$%&'  !"  !"#$%

~ 1.03); the similarities in

densities between Sylgard 184 and the density of water make efficient recovery of
elastomeric particles challenging; alternative methods to increase particle recovery during
washing steps are necessitated.
To establish if significant particle aggregation was occurring during centrifugal
washes (2900 x gravity at 2 minutes) forward scatter measurements were performed on
resuspended avidinylated-elastomeric particles in a protein-rich solution (1X PBS with
0.1% BSA) using flow cytometry (Figure 3.11). The forward light scatter intensity of
particles in suspension is a relative measure of particle size in which an increase in
average scatter intensity typically (but not always) reflects an increase in average particle
size. Prior to centrifugation the relative mean forward scatter intensity was ~ 683,658
intensity units; following the 1st centrifugal wash the mean forward scatter was ~ 707,294
units; and by the 7th wash the mean forward scatter was ~ 674,416 units. The lack of
significant alteration in the mean forward scatter intensity measurements suggest that
significant aggregation was not occurring during centrifugal washes of avidinylatedelastomeric particles suspended in a protein-rich solution; and thus the particle losses in
Figure 3.8 were unlikely to be explained by particle aggregation..
To determine if prolonged time exposure to centrifugal forces might improve
particle recovery, avidinylated-elastomeric particles in a protein-rich solution were
centrifuged at varying time-lengths at a consistently-applied centrifugal force (2900 x
gravity) (Figure 3.12).

37

Mean Forward Scatter Units

1000000
900000
800000
700000
600000
500000
400000
300000
200000
100000
0

0

1

2

3

4

5

6

7

8

Number of Centrifugal Washes

% of Elastomeric Particles Recovered

Figure 3.11 Polydisperse avidinylated-elastomeric particles (Sylgard 184) in 1X PBS
(with 0.1% BSA) do not demonstrate appreciable changes in mean light scatter intensity
during sequential centrifugal washes (2900 x gravity @ 2 minutes).
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Figure 3.12 Bar graph illustrating effect of centrifugation time on particle recovery
percentages of polydisperse avidinylated-elastomeric particles (Sylgard 184) in proteinrich solution (1X PBS with 0.1% BSA). Particles were centrifuged at 2900 x gravity.
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Centrifugally-washing avidinylated elastomeric particles (~ 3.0 x 106 particles/mL) for 2
minutes followed by resuspension in the protein-rich solution resulted in a particle
recovery of ~ 76%; 5 minutes resulted in 84%; and a 10 minute wash led to a 71%
recovery of avidinylated-elastomeric particles. These results appear to indicate that the
duration of centrifugal washes do not significantly alter the particle recovery percentage
of avidinylated-elastomeric particles in a protein-rich solution (Figure 3.12).
Avidinylated-elastomeric particles were also centrifuged at different centrifugal
forces (@ 5 minutes) to determine how the magnitude of the centrifugal force affects the
particle recovery percentage (Figure 3.13). The results demonstrated a measurable
increase in the particle recovery percentage as the centrifugal forces were increased.
Avidinylated-elastomeric particles (~9.0 x 106 particles/mL) centrifuged at 700, 2900,
and 6600 x gravity corresponded to a 78%, 88% and 95% particle recovery. These
results indicate that good particle recovery can be achieved in less than 10 min by
centrifugation at 6600 x gravity.
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Figure 3.13 Bar graph illustrating how centrifuge force is affecting the particle recovery
percentages of polydisperse avidinylated-elastomeric particles (Sylgard 184) in proteinrich solution (1X PBS with 0.1% BSA) during centrifugal washes performed for 5 minute
durations.
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Synthesis of Monodisperse Elastomeric Particles (Sylgard 184)
Monodisperse elastomeric particles were synthesized from Sylgard 184 at a 10:2
ratio of prepolymer (viscosity ~ 5000 cSt) to crosslinking agent (110 cSt), using a
PDMS-based T-junction microfluidic device (Figure 2.14A). To ensure that the PDMS
microchannels were hydrophilic, elastomeric droplet production was initiated
immediately after the PDMS microfluidic template was plasma sealed to the glass
microslide. Although monodisperse elastomeric droplets and particles were produced, the
high viscosity (2209 cSt) resulting from the 10:2 ratio of prepolymer to crosslinking
agent resulted in an exceedingly slow droplet rate (~ 1 droplet per second). To remedy
the slow droplet rate, the viscosity of the Sylgard 184 was altered to a 6:4 ratio of
prepolymer to crosslinking agent; thus resulting in a lowered viscosity (827 cSt). The
lowered viscosity (827 cSt) resulted in an increase in droplet rate to 58 droplets per
second; however droplet production was only possible for ~ 1-1.5 hours as the PDMS
microchannels rapidly reverted back to a more hydrophobic state. The droplets that were
collected were subsequently crosslinked to form elastomeric particles (Figure 2.14B)
where the size distribution (Figure 2.14C) was used to derive a mean particle size of
22.88 µm, a standard deviation of ± 1.587 µm, and a coefficient of variation of 6.9%.
To modify the hydrophobic nature of PDMS microchannels and to increase the
elastomeric droplet production time, PDMS microchannels were coated with a layer of
silica using pre-established sol-gel chemistries followed by covalent attachment of a
hydrophilic PEG-silane.29
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Figure 3.14 Elastomeric particles (Sylgard 184) with a narrowed size distribution were
synthesized using a PDMS-based T-Junction microfluidic system without surfactant. (A)
Bright field image of elastomeric particles synthesized from a 10:2 ratio of Sylgard 184
prepolymer to crosslinking agent (kinematic viscosity~ 2209 cSt). (B) Bright field image
of elastomeric particles synthesized from a 6:4 ratio of Sylgard 184 prepolymer to
crosslinking agent (viscosity~ 827 cSt) and (C) size histogram. Note: Red bar equals ~
100 µm.
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Attempts to coat freshly-sealed PDMS microchannels with a useable silica layer were
unsuccessful, as the silica layer was excessively thick resulting in a high pressure buildup
that restricted the flow of the organic PEG-silane solution. Adjustments to incubation
times of the silica precursors in the microchannels could be used to modify silica layer
thickness to allow less restricted flow of organic and aqueous solutions.
Alternative microfluidic systems were also pursued using glass capillary
devices;30 however flow rates of the continuous phase (ultra-pure water) and dispersed
phase (10:2 ratio of prepolymer to crosslinking agent) that were within an extreme
laminar flow profile (Re << 1) were not compatible with droplet production within the
glass capillary device. The use of a lower viscosity PDMS blend, e.g., 6:4 ratio of
prepolymer to crosslinking agent, may allow shearing and subsequent production of
droplets.
Monodisperse elastomeric droplets (10:2 ratio of prepolymer to crosslinking
agent) were also successfully produced using an emulsifying avidin protein (1µM) and a
flow focusing microfluidic device (Figure 3.15A and B). This experiment was done as an
attempt to produce droplets capable of binding biotinylated proteins. The size histogram
(Figure 3.15C) indicated a mean droplet size of 40.10 µm; a standard deviation of ± 0.60;
and a coefficient of variation of 1.5%. Although the droplets were extremely
monodisperse (CV~1.5%) droplets with adsorbed avidin could not be converted into
crosslinked elastomeric particles. Elastomeric droplets were clearly seen coalescing as
they were being dried on a glass slide (Figure 3.15D); which was indicative of negligible
crosslinking.
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Figure 3.15 Monodisperse Elastomeric droplets (10:2 ratio of Sylgard 184 prepolymer to
crosslinking agent) generated using a PDMS-based flow focusing device with an avidin
protein as the emulsifying surfactant. Bright field images of elastomeric droplets at (A)
10x and (B) 20x objectives, and (C) size histogram. (D) Bright field image showing
elastomeric droplets that have coalesced as they were being dried on a glass slide. Note:
red arrows indicate coalescence of droplets.
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Although the use of avidin protein as an emulsifying surfactant prevented elastomeric
droplets from crosslinking, it does demonstrate potential for using protein as surfactant
for the production of monodisperse elastomeric particles using microfluidic systems.
In a separate series of experiments, bovine serum albumin (BSA) protein was
successfully used to produce crosslinked monodisperse elastomeric particles. The reason
that BSA but not avidin was permissive of crosslinking remains to be determined.
Synthesis of Polydisperse Elastomeric Particles (low molecular weight PDMS)
Polydisperse elastomeric particles were successfully synthesized using a lower
molecular weight version of PDMS (specific gravity~0.97 and a viscosity ~ 450 cSt) with
the bulk oil-in-water emulsion process in the absence of surfactant (Figure 3.16).
To determine the amount of crosslinking agent required to produce crosslinked
elastomeric particles, it was necessary to mix different amounts of crosslinking agent into
the PDMS prepolymer prior to emulsification and thermal curing. After thermal curing,
the emulsions made with different amounts of crosslinking agent were dried on glass
slides and then imaged to determine if the elastomeric droplets had been converted into
elastomeric particles.
Emulsions prepared with 9:1 or 7:3 ratio of PDMS prepolymer to crosslinking
agent, coalesced immediately upon being dried on the glass slides (Figure 3.16A).
Emulsions prepared with 5:5, 2.5:7.5, and 1.5:8.5 ratios showed no observable
coalescence upon drying (Figures 3.16C,D, and E); therefore indicating that the
elastomeric droplets, prepared from the bulk-emulsions, had been successfully converted
into elastomeric particles upon being thermally cured.
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Figure 3.16 Polydisperse elastomeric particles can be synthesized from a low molecular
weight PDMS elastomer (viscosity~450 cSt; specific gravity ~ 0.97) when the
appropriate ratios of prepolymer to crosslinking agent are utilized. Elastomeric
droplets/particles were produced using (A) 9:1, (B) 7:3, (C) 5:5, (D) 2.5:7.5, and (E)
1.5:8.5 ratios of prepolymer to crosslinking agent. All samples were dried on a glass slide
prior to obtaining bright field images. Note: Red bar equals ~ 100 µm.
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In the absence of quantitative data, based on visual observation of the images (Figure
3.13) it appears that the elastomeric particles are getting smaller as the crosslinking agent
amount is increased. As more crosslinks are introduced into the crosslinked polymeric
network, the low molecular weight PDMS prepolymers get pulled in tighter, resulting in
stiffer (less compressible) and smaller particle sizes.
Synthesis of Monodisperse Elastomeric Particles (low molecular weight PDMS)
Synthesis of monodisperse elastomeric particles from low molecular weight
PDMS was successfully performed using PDMS-based flow focusing and T-junction
microfluidic devices with emulsifying surfactants (CTAB, SDS, and Pluronic F108). The
bright field images (Figure 3.17 A,B, and C) indicate hexagonal packing of particles;
indicative of extreme monodispersity. A flow rate of 5 µL/mL for the continuous phase
and 0.08 µL for the dispersed phase allowed a droplet rate of ~400 droplets per second
and a prolonged droplet production time of greater than 10 hours. This protocol would be
suitable for scaled up production of elastomeric particles for bioassay applications. The
use of a Pluronic F108 surfactant is advantageous in that it is biocompatible and nontoxic. Methodologies to functionalize the Pluronic F108 surfactant with a biotin moiety
have been developed28 and therefore make the use of Pluronic F108 surfactant an
attractive emulsifying agent for the production of monodisperse elastomeric particles
intended for use in biological applications (e.g., bioassays).
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Figure 3.17 Monodisperse elastomeric particles synthesized from a low molecular
weight PDMS elastomer (viscosity~450 cSt; specific gravity ~ 0.97) using PDMS-based
microfluidic devices. Monodisperse elastomeric particles synthesized using (A) a flow
focusing device in the presence of 0.1% CTAB surfactant and 20% glycerol; (B) a Tjunction device in the presence of 0.5% SDS surfactant; and (C) a flow focusing device in
the presence of 0.1% Pluronic F108 surfactant. Red bar equals ~ 100 µm.
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Conclusions and Future Directions
Bulk emulsions and microfluidic systems can be successfully utilized in the
synthesis of elastomeric particles from two varieties of PDMS (Sylgard 184 and low
molecular weight PDMS). Monodisperse elastomeric particles can be successfully
synthesized using microfluidic systems (PDMS-based flow focusing and T-junction
microfluidic devices) and PDMS elastomers; however, there are limitations when the
Sylgard 184 is used instead of the low molecular weight PDMS. To obtain a suitable
droplet rate (~58 droplets per second), Sylgard 184 (specific gravity ~ 1.03) was used at a
6:4 ratio of prepolymer to crosslinking agent (viscosity ~ 827 cSt); this blend allowed the
production of monodisperse elastomeric particles, but droplet production was only
sustainable as long as the PDMS-based microchannels maintained a hydrophilic coating
after plasma sealing. The rapid return of the PDMS microchannels to a hydrophobic state
minimized the effectiveness of this system. The use of a low molecular weight PDMS
elastomer (specific gravity ~ 0.97) appears to be an alternative approach that avoids this
problem. In the presence of emulsifying surfactants (e.g., CTAB, SDS, and Pluronic
F108) low molecular weight PDMS elastomer can be used to produce elastomeric
droplets at a suitable rate of 400 droplets per second for at least 10 hours without
interruption. A potentially promising approach for making such particles bioassay
compatible would be to substitute a biotinylated version of the emulsifying Pluronic F108
as surfactant in the production process. The presence of endogenous biotin moieties
would allow versatile adaptation of the particles to a variety of bioassay formats through
use of appropriate avidin/biotin conjugation reagents.
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Chapter 4 Elastomeric Particles Biofunctionalized and Used in Flow
Cytometry-Based Assays
Biofunctionalization of Polydimethylsiloxane (PDMS)
Functionalization of polydimethylsiloxane (PDMS) surfaces can be accomplished
by 1) chemical modification, which can lead to covalent attachments of bio(molecules) to
the surface of PDMS; or 2) physical adsorption, in which biomolecules can be nonspecifically adsorbed onto the surface. Chemical modification (i.e., covalent coupling)1 of
the PDMS surface can be a stable irreversible method for functionalizing PDMS surfaces
(e.g., microfluidic microchannels) for assay activity, but the process can be 1)
complicated, i.e., -there could be multiple steps involved in the chemical modification
process;2-4 2) time consuming; and 3) expensive in regards to purchasing many of the bioreagents needed for the process. The use of physical adsorption (also referred to as nonspecific adsorption) of (bio)molecules (e.g., avidin, IgG, Protein A/G) to the surface of
PDMS5,6 can be simple, rapid, and require few selective bio-reagents. However, the use
of physical adsorption as a method to functionalize PDMS surfaces is reversible, and may
limit the functional activity of the adsorbed (bio)molecules. Upon non-specific adsorption
of biomolecules to the surface of hydrophobic PDMS surfaces, the adsorbed
biomolecules can undergo a structural relaxation and become denatured or partially
denatured-leading to a partial loss of activity.7
As a result of chemical modification of PDMS taking multiple steps, consuming
multiple reagents, and having the potential of being a time consuming process, physical
adsorption can quite often become an attractive method to functionalize PDMS substrates
for proof-of-concept purposes. In this dissertation we define physical adsorption as the
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process where protein (e.g., avidin, BSA) or amphiphilic molecules, detergents such as
cetyltrimethylammonium bromide (CTAB), non-specifically adhere to a solid surface
(e.g., polystyrene, PDMS); the mechanism for this non-specific attachment can be based
on Van der Walls forces, hydrophobic interactions, electrostatic interactions, and
hydrogen bonding between the adsorbed (bio)molecules and the substrate.7,8
The efficiency with which protein(s) adsorb onto substrates can be dependent on
1) the physical and chemical properties of the proteins, i.e., such as their shape: globular
(e.g., bovine serum albumin: BSA) versus rod-like (e.g., fibrinogen); 2) the isoelectric
point or charge (e.g., negative or positive) of the proteins, and 3) the presence of
chemical groups on the proteins that render them more hydrophobic or capable of
hydrogen bonding with chemical groups on the substrate.7 Physical and chemical
properties of the substrate (e.g., topography: curvature and roughness of surface, size, and
chemical groups) also affect the adsorption efficiency along with the conformation and
orientation of the adsorbed proteins.7,9,10
It has been proposed that initial adsorption of bovine serum albumin (BSA, a
globular protein) and fibrinogen (rod-like protein) to hydrophobic (-CH3) and hydrophilic
surfaces (-OH) reaches equilibrium (or saturation) within the first hour of exposure with
saturating concentrations; after this time there are very few reported conformational
changes detected at the surface of adsorption using spectroscopic methods.7 Published
reports have also demonstrated that BSA and fibrinogen adsorptions are more favorable
on hydrophobic than hydrophilic surfaces.7 This is indicated by the affinity constants for
BSA adsorption on hydrophobic (Ka=5.4 M-1) and hydrophilic surfaces (Ka=5.3 M-1) and
for fibrinogen adsorption on hydrophobic (Ka=36 M-1) and hydrophilic surfaces (Ka=10.9
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M-1).7 The lower affinity constants of protein adsorption to hydrophilic (-COOH, -C-OH)
surfaces may simply reflect weak hydrogen bonding and ionic interactions between the
hydrophilic surface and nearby proteins.7
Investigations on how the surface curvature affects adsorption of proteins onto
solid-phase substrates have also been reported. The smaller the microparticles are, or the
greater the curvature is, the greater the binding affinity of BSA (or fibrinogen) will be for
solid-phase surfaces.7 It has also been reported that the greater the curvature is the
greater structural stability will be for BSA.9,10
The mechanism of protein adsorption onto hydrophobic surfaces appears to be
dominated by hydrophobic interactions.7,8 The adsorption of BSA is a 1-step process
where BSA rapidly adsorbs to the surface (Figure 4.1).7 This adsorption process occurs
through hydrophobic surface interactions from the outer layer and the inner core of the
protein. These hydrophobic interactions may cause the BSA protein to undergo partial
denaturation; thus losing some of its structural integrity and shape, i.e., undergoing
structural deformation as it strongly adsorbs to the hydrophobic surface (Figure 4.1).7
Fibrinogen, by contrast, uses a multistep approach when adsorbed onto hydrophobic
surfaces at high concentrations.7 The process consists of the initial protein adsorption
followed by rearrangement of the adsorbed proteins to form a tight, ordered monolayer
on top of the hydrophobic surface. The fibrinogen protein rearrangement may be driven
by increased hydrophobic interactions as the long axes of the proteins become aligned
parallel to each other (Figure 4.1).7
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Figure 4.1 A schematic to show adsorption of (a) a globular protein (e.g., BSA) whose
conformation may become distorted on interaction with the surface and (b) a rod-like
protein that undergoes a multistage adsorption process where (i) initially the protein
adsorbs with its long axis parallel to the surface and then (ii) rearrangement occurs to
increase protein-protein interaction and surface concentration of protein.7

It is presumed that most proteins adsorb onto hydrophobic surfaces following one
of the above-mentioned adsorption mechanism (Figure 4.1). Avidin protein is a globular
protein with a molecular mass of ~ 66,000 kilodaltons (kDa). As a result of avidin
having a similar shape (globular) and molecular mass to BSA, it could be presumed that
avidin adsorbs onto hydrophobic PDMS surfaces using an adsorption mechanism similar
to BSA. It can also be predicted that avidin adsorbs onto hydrophobic surfaces (CH3)
with a similar binding affinity constant as BSA ( 5.4 M-1).
Avidin adsorption on PDMS surfaces has not been thoroughly investigated, but
avidin has been shown to reversibly adsorb onto hydrophobic PDMS surfaces.11 Devel et
al, reported that avidin adsorbed onto hydrophobic surfaces (-CH3) can be removed by
performing a wash with a solution containing a non-ionic surfactant (octyl-β-Dglucopyranoside), which was consistent with a prevalence of hydrophobic interactions.12
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Once avidin adsorption is complete, hydrophobic PDMS surfaces can be further
functionalized by attachment of biotinylated biomolecules (e.g., small molecules,
oligomers of DNA, polysaccharides).13
Avidin (or streptavidin) is a tetrameric protein with 4 biotin-binding subunits that
are capable of being used for biotinylated biomolecule attachment (Figure 4.1). A
plethora of biotinylated biomolecules (e.g., biotinylated mouse anti human prostate
specific antigen: PSA) are commercially available and can be delivered in a ready-to-use
format. Physical adsorption of avidin onto hydrophobic PDMS surfaces (-CH3) has been
used previously as a simple and rapid method to functionalize PDMS based microfluidic
networks for bioassay applications.13 Avidin protein has a high isoelectric point (PI~10.1),
and along with its attached sugar molecules (mannose and N-glucosamine),14 gives avidin
a high propensity for non-specific binding to solid phase surfaces.15 Avidin, contains a
biotin-binding pocket on each of its 4 subunits; thus each avidin protein is capable of
binding 4 biotins. The association constant (Ka) for the avidin/biotin complex is
approximately 1015 M-1,15 and thus makes attachment of biotinylated biomolecules to
avidinylated PDMS surfaces a simple and straightforward process.3,16,17
Flow Cytometry-Based Assays
Flow cytometry was originally used to make measurements on biological cells
(e.g., blood cells) while commercially-available microbeads were primarily used for
calibration purposes; however, over the past several decades flow cytometry has become
a prominent tool in bead-based assays that are used to quantify soluble protein markers.
Enzyme linked immunosorbent assay (ELISA) is the standard method for quantifying
soluble proteins, but there are several disadvantages in ELISA that can be improved upon
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by using bead-based flow cytometry assays. ELISA only allows one type of protein assay
to be performed at a time, requires multiple washing steps, and is a relatively low
throughput method. By contrast, bead-based flow cytometry assays can be performed in a
multiplexed format, can be made high-throughput through elimination of washing steps,
and allows measurements to be performed on thousands of beads per second for
improved statistical evaluation.
In this dissertation chapter, we focus on the use of non-specific adsorption of an
avidin (or streptavidin) protein as a method for functionalizing PDMS-based elastomeric
particles. We demonstrate that 1) avidin (or streptavidin) protein can be successfully
adsorbed onto the hydrophobic surface of elastomeric particles; 2) that avidinylatedelastomeric particles can be further functionalized with a biotinylated-monoclonal
antibody; and 3) that functionalized elastomeric capture microparticles (ECµPs) can be
successfully used in homogeneous (no wash) assays where ligand capturing is performed
in high protein backgrounds prior to flow cytometry analysis.
Materials and Methods
Synthesis of Elastomeric Particles
Synthesis of Polydisperse Elastomeric Particles
Sylgard 184 (specific gravity ~ 1.03) (1 g, at 10:2 ratio of PDMS prepolymer to
crosslinking agent) or low molecular weight PDMS (specific gravity ~ 0.97) (1 g, at 1:1
ratio of PDMS prepolymer to crosslinking agent) (Dow Corning Corp., Midland, MI)
were emulsified in 10 mL of ultrapure water (18.2 MΩ•cm @ 25 °C; Synergy®, EMD
Millipore) using a homogenizer (Power Gen 125, Fisher Scientific) set at 6,000 RPM for
~ 60 seconds. The elastomeric droplets, with crosslinking agent, were cured at 100 °C for
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~ 1 hour to form crosslinked elastomeric particles. Elastomeric particles were imaged
using bright field microscopy (BH-2, Olympus) and a 4300 cool pix camera (Nikon). The
scale bar was calibrated based on standardized monodisperse particles (mean diameter =
30.1 µm; standard deviation = ± 2.1 µm; and a coefficient of variation = 6.6%) (Thermo
Scientific).
Synthesis of Monodisperse Elastomeric Particles
Sylgard 184 (6:4 ratio of PDMS prepolymer to curing agent) was used to form
PDMS-based elastomeric droplets in a PDMS-based T-junction microfluidic device. The
continuous phase contained ultrapure water (18.2 MΩ•cm @ 25 °C; Synergy®, EMD
Millipore) that was filtered with a 0.22 µm pore sized Acrodisc® syringe filter (PALL
Corp., Port Washington, NY). To help prevent droplets from wetting the micro channel
walls, the continuous phase was first injected using a syringe pump (Nexus 3000,
Chemyx Inc. Stafford, TX) at a flow rate of 5-13 µL/min, into the freshly sealed
microfluidic device. The dispersed phase (Sylgard 184) was then injected into the
microfluidic device using a syringe pump (Nexus 3000, Chemyx Inc. Stafford, TX) at a
flow rate of 0.67 µL/min. Monodisperse elastomeric droplets were then collected off chip
and cured in an oven (Model 1321F, VWR International, Cornelius Oregon) overnight at
70 °C.
Functionalization of Polydisperse Elastomeric Particles
Avidin Adsorption
Polydisperse elastomeric particles (2.5 x 107 particle/mL) from Sylgard 184 (10:2
ratio of prepolymer to crosslinking agent) and low molecular weight PDMS (1:1 ratio of
prepolymer to crosslinking agent) were incubated in a 1 µM avidin-FITC (Molecular
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Probes, Eugene, Oregon) solution in 1 mL of 1X PBS for 30 minutes at room temperature
with continuous rocking. Elastomeric particle solutions were subsequently centrifugallywashed (2900 x gravity at 2 minutes) and then imaged using an epifluorescence
microscope (Zeiss Axio Imager) and a Luca S EMCCD camera (Andor Technology,
Belfast N., Ireland) with Andor imaging software (Andor-Solis) and an inverted
fluorescence microscope (Zeiss Axiotron; model: AXT03) with a Hitachi CCD digital
camera (model: KPD591U).
Adsorption Studies
Polydisperse elastomeric particles (2.5 x 107 particles/mL) (10:2 ratio of Sylgard
184 prepolymer to crosslinking agent) were incubated in a 1 µM avidin-FITC solution in
a total volume of 1 mL of 1X PBS for 30 minutes at room temperature with continuous
rocking. The elastomeric particles with the adsorbed avidin-FITC were then analyzed
with flow cytometry and then centrifuged 4 x sequentially for 5 minutes at different
centrifugal forces (700, 2900, 6000, and 14,000 x gravity). After centrifugation and
gentle removal of the supernatant, the elastomeric particles were resuspended in a 1X
PBS (with 0.1% BSA) solution followed by flow cytometry analysis. Flow cytometry
analysis was performed after every centrifugal wash/resuspension cycle.
Polydisperse elastomeric particles (1.0 x 107 particles/mL) (10:2 ratio of Sylgard
184 prepolymer to crosslinking agent) were incubated with 30 nM streptavidinphycoerythrin (PE) (Invitrogen, Eugene, Oregon) or 1 µM unconjugated avidin protein
(Molecular Probes, Eugene, Oregon) in 500 µL of 1X PBS at room temperature with
continuous rocking for 30 minutes. Elastomeric particles with adsorbed streptavidin-PE
were then centrifugally washed (2900 x gravity for 5 mins) then analyzed using flow
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cytometry (Accuri C6). Elastomeric particles (~5.0 x 106 particle/mL) with streptavidinPE were then incubated in 1 mL of PBS with 0.003% tween 20 or 0.1% bovine serum
albumin (BSA) (Sigma-Aldrich) for ~ 30 minutes at room temperature with continuous
rocking. Samples were then centrifugally washed and analyzed with flow cytometry.
Elastomeric particles (5.0 x 106 particles/mL) with adsorbed avidin protein were
incubated with a 100 nM solution of BSA conjugated to AlexaFluor-647 (Invitrogen,
Eugene, Oregon) in 1 mL of 1X PBS for 30 minutes at room temperature with continuous
rocking. Samples were then centrifugally washed and analyzed using flow cytometry.
Avidin and Streptavidin Titrations
Polydisperse elastomeric particles (2.5 x 107 particles/mL) (10:2 ratio of Sylgard
184 prepolymer to crosslinking agent) were incubated with different concentrations of
avidin-FITC (0, 20, 40, 80, 100 and 1000 nM) and streptavidin AlexaFluor-647
(Invitrogen, Eugene, Oregon) (0, 20, 40, 80, and 100 nM) in 1 mL of 1X PBS for 30
minutes at room temperature at continuous rocking. Samples were then centrifugallywashed (2900 x gravity for 5 minutes) and then analyzed using flow cytometry (Accuri
C6).
IgG Titration
Polydisperse elastomeric particles (2.5 x 107 particle/mL) were incubated
in 1 µM of unconjugated avidin (Molecular Probes, Eugene, Oregon) in a total volume of
1 mL of 1X PBS for 30 minutes at room temperature with continuous rocking.
Avidinylated-elastomeric particles were then centrifugally-washed (2900 x gravity for 5
minutes) and resuspended in 1 mL of the washing blocking buffer (1X PBS with 0.1%
BSA) where they were incubated for 30 minutes at room temperature with continuous
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rocking. The avidinylated-elastomeric particles (5.0 x 106 particle/mL) in 1 mL of 1X
PBS were then incubated with varying concentrations (0, 2, 4, 6, and 8 nM) of the
biotinylated mouse anti human PSA monoclonal IgG (Abcam, Cambridge, MA) for 30
minutes at room temperature with continuous rocking. Elastomeric capture microparticles
(ECµPs) were then centrifugally-washed and resuspended in 500 µL of the washing
blocking buffer after which the samples were incubated with a 7 nM solution of goat anti
mouse IgG-phycoerythrin (PE) (Abcam, Cambridge, MA) for 30 minutes at room
temperature with continuous rocking. The elastomeric particles were then analyzed using
flow cytometry.
Prostate Specific Antigen (PSA) Titrations (no wash)
Five x 105 ECµPs –elastomeric particles functionalized with mouse anti-human
PSA monoclonal antibodies (HyTest Inc., Turku, Finland)– were incubated with different
concentrations (0, 1, 5, 10, 20, 30 nM) of prostate specific antigen (PSA) (Meridian Life
Sciences Inc., Memphis, TN) in 200 µL (or 20 µL) of aqueous media (1X PBS with 1
mg/mL of BSA and 10% human plasma diluted with PBS containing 1 mg/mL of BSA)
for 30 minutes with continuous rocking at room temperature. Without washing, enough
mouse anti-human PSA monoclonal antibody-FITC (detection antibody) (HyTest Inc.,
Turku, Finland) was added to make a 1 nM solution that was incubated for 30 minutes
with rocking at room temperature. The ECµPs were then analyzed with an Accuri C6
flow cytometer without washing. All bioassay data was fitted to a one-site binding curve
with the following equation, 𝑌 =

!!"# ∗!
!! !!

using PRISM (Graph Pad) version 5.0b. The

dependent variable (Y) is the median fluorescence intensity (MFI, y-axis), the
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independent variable (x) is the ligand analyte concentration (x-axis), Kd is the
dissociation constant and Fmax is the maximum MFI.
Functionalization of Monodisperse Elastomeric Particles
Monodisperse elastomeric microparticles (~105 particles/mL) were incubated in 1
µM avidin (Molecular Probes, Eugene, Oregon) or streptavidin-Alexa Fluor® 647
conjugate (Invitrogen, Eugene, Oregon) in 1X PBS for 30 minutes at room temperature
with continuous rocking. Elastomeric particles were then centrifugally washed (1200 x
gravity for 15 minutes). The supernatant was gently removed and the particles were then
resuspended in the washing/blocking buffer (1X PBS with 0.1 % BSA). A biotinylated
mouse anti human high density lipoprotein (HDL) monoclonal antibody (Abcam,
Cambridge, MA) was then added to make a ~ 7 nM solution; the solution was incubated
for 30 minutes at room temperature with continuous rocking. Elastomeric capture
microparticles (ECµPs) were then centrifugally washed and resuspended in the
washing/blocking buffer. Detection of the attached monoclonal antibody was performed
by incubating ECµPs in a 7 nM solution of goat anti mouse IgG-phycoerythrin (PE)
(Abcam, Cambridge, MA) for 30 minutes at room temperature with continuous rocking
followed by flow cytometry analysis.
Flow Cytometry Analysis
An Accuri C6 flow cytometer (BD Biosciences) was used for all flow cytometry
analyses. Green fluorescence (e.g., FITC) and orange fluorescence (e.g., PE) of particles
were excited at 488 nm and detected at 530 nm ± 40 nm and 580 ± 40 nm, respectively.
Red fluorescence of Alexa-640 was excited at 635 nm and detected at 675 ± 25 nm.
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Fluorescence and light scatter intensities were recorded as arbitrary units on a relative
scale ranging from 10 to 6,500,000.
Results
The hydrophobic surface of PDMS-based materials (e.g., PDMS-based
microfluidics) allows for the non-specific adsorption of proteins. Generally this has been
interpreted as a negative attribute associated with PDMS. In this dissertation report, we
can demonstrate that it is possible to utilize the natural biofouling nature of PDMS
materials to functionalize PDMS-based elastomeric particles using the non-specific
adsorption of avidin protein (Figure 4.2) followed by further functionalization via
attachment of biotinylated biomolecules.
avidin

Sylgard 184
Particle

+

Incubate
30 minutes

avidin

Sylgard 184
Particle

Figure 4.2 Non-specific adsorption of avidin protein onto the hydrophobic surface of
elastomeric particles.
Functionalization of Polydisperse Elastomeric Particles
Avidin Adsorption
Polydisperse elastomeric particles synthesized from PDMS-based elastomers
using the bulk-emulsion process in the absence of surfactant, were functionalized using
non-specific adsorption of avidin-FITC (Figure 4.3). The fluorescent images indicate
that a large molecular weight PDMS elastomer (10:2 ratio of Sylgard 184 prepolymer to
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crosslinking agent) (Figure 4.3A) along with a low molecular weight PDMS elastomer
(1:1 ratio of low molecular weight PDMS prepolymer to crosslinking agent) (Figure
4.3B) can be easily functionalized with non-specific avidin adsorption.
Adsorption Studies
The adsorption of avidin protein to the hydrophobic surface of polydisperse
elastomeric particles (Sylgard 184) resulted in a strong attachment that resisted
desorption under the influence of strong shear forces that were generated via
centrifugation. The synthesized elastomeric particles (~2.5 x 107 particles/mL) that were
initially analyzed with flow cytometry showed a median fluorescence intensity (MFI) of
252 (Figure 4.4). Once avidin-FITC adsorption was performed on the elastomeric
particles, the MFI increased to 6,962 (Figure 4.4). After performing a centrifugal wash at
700 x gravity in the washing blocking buffer (1X PBS with 0.1% BSA) the MFI of the
particles was 9,605; the subsequent centrifugal-washes on the same sample in the
washing blocking buffer were performed at 2900, 6600, and 14000 x gravity
demonstrated MFIs of 9,412, 8,833, and 9,598, respectively (Figure 4.4). These results
demonstrated no appreciable loss of fluorescence on the measured particles; thus
indicating that the adsorbed avidin-FITC was not being removed from the elastomeric
particles during centrifugal-washes performed at high centrifugal forces.
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Figure 4.3 Non-specific adsorption of avidin-FITC protein onto polydisperse elastomeric
particles synthesized from (A) Sylgard 184 and (B) low molecular weight PDMS. Note:
Red bar equals ~ 100 µm
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Figure 4.4 Avidin-FITC maintains non-specific adsorption to the surface of polydisperse
elastomeric particles (Sylgard 184) subsequent to multiple washes involving high
centrifugal forces.
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To establish if surfactants (detergents) were capable of removing adsorbed
protein from the surface of polydisperse elastomeric particles (Sylgard 184), elastomeric
particles (~5.0 x 106 particle/mL) with adsorbed streptavidin-PE were incubated with a
0.003% tween 20 solution. The elastomeric particles were centrifugally washed and then
analyzed with flow cytometry where the particles were identified and gated for
fluorescence analysis on the basis of their light scattering distribution profile (forward
scatter versus side scatter plot) (Figure 4.5A). The initial MFI of the elastomeric particles
with adsorbed streptavidin-PE was 17,792 (Figure 4.5B). Once the elastomeric particles
with adsorbed streptavidin-PE were incubated with a solution of 0.003% tween 20 and
centrifugally washed, the MFI plummeted to 479 (Figure 4.5B); indicative that the tween
20 had removed a significant amount of the adsorbed streptavidin-PE from the surface of
the elastomeric particles.
To evaluate the affects of incubating protein-functionalized elastomeric particles
in the presence of other soluble proteins, elastomeric particles (5.0 x 106 particles/mL)
with adsorbed streptavidin-PE were incubated with a solution of 0.1% BSA and then
centrifugally washed. The initial MFI of the elastomeric particles with adsorbed
streptavidin-PE was 13,078 (Figure 4.5C). Once the elastomeric particles with adsorbed
streptavidin-PE were incubated with a solution of 0.1% BSA the particles displayed a
MFI value of 13,163 (Figure 4.5C); indicative that the soluble BSA protein does not
remove the adsorbed streptavidin-PE from the surface of the elastomeric particles.
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Figure 4.5 Protein non-specifically adsorbs to the hydrophobic surface of polydisperse
elastomeric particles (Sylgard 184). (A) A density scatter plot (forward scatter versus side
scatter) was used to identify elastomeric particles. (B) Elastomeric particles were treated
with streptavidin-phycoerythrin (PE)(black trace) followed by incubation with 0.003%
tween 20 (orange trace). (C) Elastomeric particles were treated with streptavidin-(PE)
(black trace) followed by incubation with 0.1% BSA (orange trace). (D) Avidinylatedelastomeric particles (orange trace) were incubated with BSA conjugated to AlexaFluor647 (black trace). Note: The density scatter plot was performed using an inverse grayscale where the darkest parts indicate the most densely populated areas and the lightest
parts indicate the least densely populated areas of the scatter plot. 96% of all detected
particles fell within the light scatter region that was selected (gated) for fluorescence
analysis.
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To determine if BSA protein can be adsorbed to the surface of elastomeric particles that
have already undergone avidin (unconjugated) protein adsorption, avidinylatedelastomeric particles (5.0 x 106 particles/mL) were incubated with a solution of BSA
conjugated to AlexaFluor-647 and then centrifugally washed. The initial MFI of the
avidinylated-elastomeric particles was 512 (Figure 4.5D). Upon incubation with a 100
nM solution of BSA AlexaFluor-647 the particles displayed a MFI value of 452,220
(Figure 4.5D); indicative that avidinylated-elastomeric particles adsorb soluble BSA
protein in solution. Adsorption of high quantities of BSA AlexaFluor-647 to the surface
of elastomeric particles may also reflect the non-specific binding of the AlexaFluor
component of the labeled BSA to the particles.
Avidin and Streptavidin Titrations
Avidin-FITC and streptavidin-PE titration curves were performed on polydisperse
elastomeric particles (2.5 x 107 particles/mL) to ascertain an approximate concentration
range that could be used to saturate the surface of elastomeric particles. Centrifugalwashes were performed on all samples prior to performing flow cytometry
measurements. The avidin-FITC titration (0, 20, 40, 80, 100 and 1000 nM) did not appear
to give any type of trend that could be used for a best-fit curve; however, a 100 nM
concentration of avidin-FITC corresponded to the highest MFI value (~ 11,640)
measured using flow cytometry (Figure 4.6A). In regards to the avidin-FITC titration,
inclusion of 200 and 400 nM concentrations would have likely provided a better binding
curve.
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Figure 4.6 Polydisperse elastomeric particles were used in (A) avidin-FITC and (B)
streptavidin AlexaFluor-647 titrations. For (A) Error bars indicate SD of 2 separate
determinations.
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A streptavidin AlexaFluor-647 titration (0, 20, 40, 80, and 100 nM) was also performed
and was successfully fit to a 1-site binding curve (Langmuir Isotherm: R2= 0.99 and Kd=
15.23 nM) using GraphPad PRISM version 5.0b (Figure 4.6B). Based on the 1-site
binding curve it appears that saturation occurs around 60-100 nM.
Functionalization with a Biotinylated Antibody
Once elastomeric particles have been functionalized with an avidin (or
streptavidin) protein, elastomeric particles can be further functionalized with a
biotinylated antibody to form elastomeric capture microparticles (ECµPs). The attached
biotinylated antibodies can then be easily detected and quantified using a secondary
antibody conjugated to a fluorochrome (e.g., phycoerythrin) along with flow cytometry
analysis (Figure 4.7).

PE

Biotinylated capture antibody

Goat anti mouse
antibody-PE

Avidin

Sylgard 184
Particle

Figure 4.7 Schematic diagram showing an attached biotinylated antibody (e.g., mouse
anti human PSA) on the surface of avidinylated-elastomeric particles being detected by a
secondary antibody (e.g., goat anti mouse IgG) conjugated to a phycoerythrin (PE)
fluorochrome.
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Avidinylated-elastomeric particles were prepared by incubation with
unconjugated avidin at a concentration of 1 µM (~10 times the maximal binding
concentration) for 30 min. To form elastomeric capture microparticles (ECµPs),
avidinylated-elastomeric particles (5.0 x 106 particles/mL) were centrifugally washed and
then incubated with varying concentrations (0, 2, 4, 6, and 8 nM) of a biotinylated
antibody (mouse anti human monoclonal IgG). ECµPs were then centrifugally washed
prior to being detected using a goat anti mouse IgG conjugated to phycoerythrin (PE) in
conjunction with flow cytometry (Figure 4.8). The biotinylated-IgG titration did not
demonstrate any type of trend that could be used for a best-fit curve; however, a 6 nM
concentration of biotinylated-IgG corresponded to the highest MFI value (~ 23,971). It
appears that maximal levels of binding may be expected in the presence of 4-6 nM of the
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Figure 4.8 Polydisperse avidinylated-elastomeric particles used in an IgG (biotinylatedmouse anti human PSA monoclonal) titration that was detected and quantified using a
goat anti mouse polyclonal-phycoerythrin and flow cytometry analysis. Error bars
indicate SD of 2 separate determinations.
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Prostate Specific Antigen (PSA) Titrations (no wash)
Polydisperse ECµPs can be used in a human prostate specific antigen (PSA) assay
that is detected and quantified using a sandwich assay configuration and flow cytometry
analysis (Figure 4.9). To ensure ultra-specific detection of PSA in solution, a monoclonal
pair of PSA antibodies were used. The biotinylated monoclonal capture antibody was
specific for epitope 1 on human PSA, and the monoclonal detection antibody-(FITC) was
specific for epitope 5 on human PSA.
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PSA monoclonal antibody-FITC
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Figure 4.9 Polydisperse elastomeric capture microparticles (ECµPs) (10:2 ratio of
Sylgard 184 prepolymer to crosslinking agent) are used to detect and quantify prostate
specific antigen (PSA) in solution utilizing a sensitive sandwich immunoassay
configuration in conjunction with flow cytometry analysis.
Polydisperse ECµPs (5.0 x 105 particles/mL) were successfully used in a
homogeneous (no wash) human PSA sandwich assay where the specific and selective
capturing of PSA occurred in 200 µL of 1X PBS with a high protein background (~ 1
mg/mL BSA). The PSA titration (0, 1, 5, 10, 20, and 30 nM) was successfully fit to a 1site binding curve (R2= 0.997; Kd = 1.141 nM) and demonstrated low non-specific
binding of the human PSA antigen (Figure 4.10A). The lowest detected PSA
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concentration was 1 nM and demonstrated very low background indicative that lower
concentrations of PSA may be possible in simple buffer solutions with high protein
content.
To determine if polydisperse ECµPs could be utilized in affinity capture assays
conducted in small liquid volumes, ECµPs (50,000 particles/mL) were utilized in a
human PSA sandwich assay where capturing of PSA occurred in 20 µL of PBS with a
high protein content. The PSA titration was successfully fit to a 1-site binding curve (R2 =
0.987) and demonstrated low non-specific binding of the human PSA antigen (Figure
4.10B). The lowest detected PSA concentration was 1 nM and demonstrated very low
background that is suggestive that detection of lower PSA concentrations are possible in
small liquid volumes with high protein content. The dissociation constant (Kd = 13.40
nM) that was calculated from the fitted 1-site binding curve was significantly higher than
the Kd value calculated from Figure 3.11A (Kd = 1.141 nM). The increased Kd value may
be the result of a decrease in the mixing efficiency that occurred because of the small
volume (20 µL) that was used for the capturing of the PSA antigen. Small volumes in
500 µL PCR tubes may allow surface tension to minimize the mixing efficiency of the
liquid within the tube; thus a lack of mixing can minimize the association of the ligand to
the receptor, therefore leading to an increase in the calculated Kd value.
To evaluate if polydisperse ECµPs could be utilized in affinity capture assays in
human plasma, ECµPs (5.0 x 105 particles/mL) were successfully used in a PSA
sandwich assay performed in 200 µL of 1% human plasma (diluted in 1X PBS with high
protein content). The PSA titration was successfully fit to a 1-site binding curve (R2=
0.986; Kd = 1.071 nM) and demonstrated low non-specific binding of the human PSA
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antigen (Figure 4.10C). The lowest detected PSA concentration was 1 nM and
demonstrated very low background indicative that lower concentrations of PSA may be
possible in biological milieu (e.g., plasma, blood). However, since there appears to be no
inflection to the fitted curve, it may be likely that the actual saturation (Bmax) of the
binding curve is much higher than the one derived from the fitted 1-site binding curve.
As a result of this, the actual Kd may be higher than the one calculated from our fitted
data.
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Figure 4.10 Elastomeric capture microparticles (ECµPs) capture human PSA in high
protein backgrounds prior to detection antibody treatment and flow cytometry analysis.
(A) 5.0 x 105 ECµPs capture human PSA in 200 µL of 1 mg/ml BSA in PBS , (B) 50,000
ECµPs capture human PSA in 20 µL of 1 mg/ml BSA in PBS , and (C) 5.0 x 105 ECµPs
capture human PSA in 200 µL of 1% human plasma that was diluted with PBS
containing 1 mg/ml BSA. Note: ( ■ ) denotes ECµPs with capture antibody and ( ● )
denotes particles without capture antibody.
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Functionalization of Monodisperse Elastomeric Particles
Monodisperse elastomeric particles synthesized using a 6:4 ratio of Sylgard 184
prepolymer to crosslinking agent with a PDMS-based T-junction microfluidic system,
can be functionalized with the same avidin/biotin conjugation reagents that were utilized
to form the polydisperse ECµPs. To identify the appropriate monodisperse elastomeric
particle population using flow cytometry, a density scatter plot (forward scatter versus
side scatter) using an inverse gray-scale was utilized (Figure 4.11A). The gated
monodisperse elastomeric particles displayed a forward scatter coefficient of variation
(CV) of ~ 3.91%; however, the gated particles only amounted to 26% of the total
particles counted using the flow cytometer. As a result of this, filtering methodologies
can be incorporated to reduce the presence of unwanted particle populations (e.g.,
satellite particles); it is hypothesized that these unwanted particles may have arisen as a
result of the microchannels in the PDMS-based microfluidic device reverting back to
their hydrophobic nature and thus resulting in less control over the size distribution of the
produced droplets and particles.
The monodisperse elastomeric particle population displayed an initial
autofluorescence MFI of 2053 (Figure 4.9B). Once the elastomeric particles were
incubated with 1 µM streptavidin AlexaFluor-647 (~66 x the Kd to achieve binding
saturation) the MFI increased to ~ 8.8 x 106; indicative that streptavidin had been
successfully adsorbed to the surface of the monodisperse elastomeric particles (Figure
4.11B).
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Figure 4.11 A monodisperse elastomeric particle population (6:4 ratio of Sylgard 184
prepolymer to crosslinking agent) was functionalized using non-specific adsorption of
avidin and streptavidin followed by further functionalization using a biotinylated high
density lipoprotein (HDL) antibody. (A) Density scatter plot (forward versus side scatter)
indicating the appropriate monodisperse particle population used for analysis. (B)
Fluorescence histogram comparing untreated elastomeric particles (red trace) to
elastomeric particles treated with streptavidin AlexaFluor-647 (yellow trace). (C)
Fluorescence histogram comparing avidinylated-elastomeric particles that were not
treated with the biotinylated HDL antibody (mouse anti human HDL IgG) prior to
centrifugal washes and secondary antibody treatment (goat anti mouse IgGphycoerythrin) (red trace) to avidinylated-elastomeric particles that were treated with the
biotinylated HDL antibody prior to centrifugal washes and secondary antibody treatment
(green trace).
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To determine if avidinylated-elastomeric particles were capable of binding biotinylated
IgGs to become ECµPs, avidinylated-elastomeric particles (pre-incubated 30 min with 1
µM unconjugated avidin) were centrifugally washed and then incubated with a solution
of biotinylated high density lipoprotein (HDL) antibody (mouse anti human HDL IgG).
Detection of the attached biotinylated HDL antibody was accomplished by performing
centrifugal washing to remove unbound biotinylated antibody followed by incubation
with a secondary antibody (goat anti mouse IgG antibody-PE) and flow cytometry
analysis. To determine the non-specific binding of the secondary antibody, a control was
also performed in which the avidinylated-elastomeric particles were incubated (without
the biotinylated-IgG) with just the secondary antibody prior to flow cytometry analysis.
The avidinylated-elastomeric particles that were incubated with only the secondary
antibody, displayed an initial MFI of ~ 1031 (Figure 4.9C). Avidinylated-elastomeric
particles that were incubated with the biotinylated IgG prior to centrifugal washes and
secondary antibody treatment displayed a MFI of ~ 57,240 (Figure 4.9C); indicative that
the biotinylated-IgG was successfully attached to the surface of the avidinylatedelastomeric particles.
Conclusions and Future Directions
Polydisperse elastomeric particles synthesized from Sylgard 184 (10:2
prepolymer to crosslinking agent) and low molecular weight PDMS (1:1 prepolymer to
crosslinking) can be easily functionalized with an avidin or streptavidin protein using
non-specific adsorption. The adsorption of avidin-FITC protein to the hydrophobic
surface of polydisperse elastomeric particles (Sylgard 184) is a relatively strong
attachment but can be easily removed by incubation in a surfactant solution (0.003%
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tween 20). Once the polydisperse elastomeric particles are functionalized with an
unconjugated avidin protein, the 4-biotin binding pockets that are associated with an
avidin protein allow further functionalization with commercially-purchased biotinylated
antibodies. In this report, the polydisperse elastomeric particles were functionalized into
elastomeric capture microparticles (ECµPs) that were successfully used in PSA sandwich
assays that were conducted in high protein content backgrounds (physiologic buffer,
exceedingly small liquid volumes, and 1% human plasma) followed by flow cytometry
analysis without prior washing. Our results demonstrated that polydisperse ECµPs have
potential to be used in homogeneous (no wash) medically-relevant bioassays (e.g., high
density lipoprotein) where the capturing of analytes is specifically and selectively
performed in high protein backgrounds (e.g., plasma, blood, cerebral spinal fluid, urine)
followed by flow cytometry analysis.
The sensitivity of assays performed with ECµPs in conjunction with flow
cytometry analysis can be enhanced by using monodisperse ECµPs. A monodisperse
elastomeric particle population synthesized from Sylgard 184 (6:4 ratio prepolymer to
crosslinking) was successfully functionalized with avidin adsorption followed by
biotinylated high density lipoprotein (HDL) antibody attachment. However, the density
scatter plot (forward scatter versus side scatter) derived from flow cytometry
demonstrated that there were a significant percentage of apparent elastomeric particles (~
74%) outside the region representing larger, more uniformly sized particles. The presence
of unwanted ECµPs can function as ligand-depletion agents; thus leading to a decrease in
the sensitivity and accuracy of the measurements being performed on gated ligand-bound
ECµPs using flow cytometry. Mechanical filtering methods may be implemented to
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remove a significant fraction of these unwanted particles prior to performing ligand
capturing and flow cytometry analysis. However, the current methods used for
synthesizing monodisperse elastomeric particles from Sylgard 184 (6:4 ratio of
prepolymer to crosslinking agent) in microfluidic devices were limited with respect to the
number of particles that could be produced from a single chip (~150,000 particles); thus
limiting the ability to efficiently scale up production for bioassay applications. The use of
a relatively hydrophilic polymethylmethacrylate (PMMA) polymer have been shown to
produce microfluidic devices that generate monodisperse elastomeric particles.6 The use
of PMMA may allow increased production of our monodisperse elastomeric particles;
thus allowing them to be used for bioassay purposes.
As indicated above in chapter 3,monodisperse elastomeric particles can be
synthesized from Pluronic F108 surfactant for long stretches of time (10 hours) at a
suitable rate (~ 400 droplets/hour) leading to 1.5 x 107 particles using microfluidic
systems. Thus, a potentially promising alternative route for producing large numbers of
monodisperse particles would be to synthesize them from a low molecular weight PDMS
in combination with a biocompatible Pluronic F108 surfactant that has already been
chemically modified with a biotin functional group. Evaluation of such an approach
remains for future investigations beyond the scope of projects associated with this
dissertation.
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Chapter 5 Elastomeric Particles Function as Negative Acoustic
Contrast Particles

Acoustic Contrast Factor
Biological cells (erythrocytes, spores, fungi, phagocytes), common sediments,
plastics, sand, metals,1 and commercially-available microspheres (e.g., Spherotech) have
a positive acoustic contrast value (Figure 5.1) and therefore function as positive acoustic
contrast particles and are acoustically forced to pressure nodes under an acoustic standing
wave.2 Because all biological cells and most commercially-available microspheres
function as positive acoustic contrast particles, the use of acoustic-based separations,
based on acoustic contrast, have rarely been implemented in biological problems1 (e.g.,
acoustic separation of ligand-bound capture particles from cells in a biological sample).
As a result of this, the development of a particle that functions as a negative acoustic
contrast particle is highly desirable and promising for biological applications (Figure 4.1).

Commercially-available microspheres
Bacteria Spores
Fungi

Negative
Acoustic Contrast
Particles

Phagocytes

Common Sediments
Plastics

Erythrocytes
0

Sand

Metals

Contrast Factor

Figure 5.1 Schematic diagram of contrast factors of various materials. Figure modified
and reproduced from Kaduchak et al.1
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Secondary Acoustic Forces
Interesting acoustic phenomena that can affect the focusing and separation of
acoustically active particles (e.g., negative and positive acoustic contrast particles) under
an acoustic standing wave field are acoustic secondary forces - also referred to as
Bjerknes forces 𝐹𝐵 (𝑥).3 These interparticle forces are caused by acoustic waves that are
scattered by particles in close proximity and can produce attractive and repulsive forces
in which the magnitude of 𝐹𝐵 (𝑥) is described by an equation reported by Crum et al.4

𝐹𝐵 (𝑥)    =   4𝜋𝑟
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The magnitude of the secondary acoustic force 𝐹𝐵 (𝑥) is directly proportional to the
radius of the particle (𝑟), the distance between particles (𝑑), the angular frequency of the
particle (𝜔) also referred to as 2πf, the density of the particle (𝜌𝑝 ) and the surrounding
medium (𝜌𝑜 ), and the compressibility of the particle (𝛽𝑝 ) and the surrounding medium
(𝛽𝑜 ). The second term
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dependent upon the velocity amplitude (𝑣 𝑥 ), where the third term
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the right side of the equation is dependent upon the pressure amplitude (𝑝 𝑥 ). A negative
value (-) for 𝐹𝐵 (𝑥) exerts attractive forces moving particles together to form aggregates
at their respective nodal (or antinodal) regions. However a positive value (+) generates
repulsive forces moving particles away from one another. An important factor
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determining the sign (+ or -) of 𝐹𝐵 (𝑥) is the angle (𝜃) and orientation of the particles
within the primary acoustic standing wave field, where θ is the angle between the line
defined by the center of two particles and the direction of the propagated primary
acoustic standing wave. If particles are lined up parallel to the propagation of the primary
acoustic standing wave, the value for θ will become 0° and therefore cos 𝜃 = 1; and thus
the velocity amplitude-dependent expression will likely have a positive value. A positive
value for the velocity amplitude-dependent expression of the equation will likely allow a
positive value for 𝐹𝐵 (𝑥); thus generating repulsive Bjerknes forces. However, if particles
are lined up perpendicular to the direction of the propagated primary acoustic standing
wave, the value for θ will become 90° and therefore cos 𝜃 =   0; and thus the velocitydependent expression becomes zero. A zero value for the velocity amplitude-dependent
expression makes the sign (+ or -) of 𝐹𝐵 (𝑥) dependent upon the pressure amplitudedependent expression making it likely that the pressure amplitude-dependent expression
will be greater than the velocity amplitude-dependent expression of the equation (0
value); thus giving a negative value for 𝐹𝐵 (𝑥) and generating attractive Bjerknes forces.
The elastomeric particles that are synthesized in this dissertation report from
PDMS elastomers, Sylgard 184 (specific gravity ~ 1.03) and low molecular weight
PDMS (specific gravity ~ 0.97), have densities that are similar to aqueous solutions ~1
g/cm3. As a result of the density similarities, the value of the velocity amplitudedependent expression of the Bjerknes force equation (1) becomes 0, and thus the
magnitude and sign (+ or -) becomes dependent on the pressure amplitude-dependent
expression of the equation; and thus, as long as there is a voltage applied to the
piezoelectric transducer to generate a pressure amplitude, the value of 𝐹𝐵 (𝑥) will be (-)
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and generate attractive Bjerknes forces. As a result of this, it appears reasonable to
conclude that any Bjerknes forces associated with elastomeric particles will likely be in
the form of attractive interparticle forces.
In this dissertation, we hypothesize that compressible PDMS-based elastomeric
particles function as negative acoustic contrast particles under an ultrasonic acoustic
pressure standing wave and that elastomeric particles can be affected by attractive forces
that cause aggregates to form at pressure antinodes. This report demonstrates 1) the
negative acoustic contrast properties of elastomeric particles that were synthesized from
two PDMS-based elastomers, Sylgard 184 (specific gravity ~ 1.03) and low molecular
weight PDMS (specific gravity ~ 0.97); and 2) the application of using an ultrasonic
acoustic pressure standing wave to separate elastomeric negative acoustic contrast
particles from positive acoustic contrast particles (blood cells and commercially-available
polystyrene particles); and 3) elastomeric particles being affected by attractive forces,
that cause elastomeric particles to clump at pressure antinodes.
Materials and Methods
Synthesis of Polydisperse Elastomeric Particles
Sylgard 184 (specific gravity ~ 1.03) (1 g, at 10:2 ratio of PDMS prepolymer to
crosslinking agent) or low molecular weight PDMS (specific gravity ~ 0.97) (1 g, at 1:1
ratio of PDMS prepolymer to crosslinking agent) (Dow Corning Corp., Midland, MI)
were emulsified in 10 mL of ultrapure water (18.2 MΩ•cm @ 25 °C; Synergy®, EMD
Millipore) using a homogenizer (Power Gen 125, Fisher Scientific) set at 6,000 RPM for
~ 60 seconds. The elastomeric droplets, with crosslinking agent, were cured at 100 °C for
~ 1 hour to form crosslinked elastomeric particles.
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Silicon Acoustofluidic Device
A silicon acoustofluidic device was fabricated in silicon via photolithography
using a photomask designed from AutoCAD software (Autodesk Inc., San Rafael, CA)
and deep reactive ion etching (DRIE) using a protocol described by Suthanthiraraj et al.5
DRIE allowed specific micro-channel patterns to be etched onto the surface of the silicon
wafer (WaferNet Inc., San Jose, CA). A borosilicate glass slide (Borofloat 33, Schott
North America, Inc., Elms Ford, NY) with 1 mm holes drilled through it to accommodate
inlet and outlet ports (tube connection sites) was then sealed on top of the etched silicon
wafer using anodic bonding.6 To allow easy insertion of silicone tubing (Cole-Parmer
Instrument Company, Vernon Hills, IL) into inlet and outlet ports, square PDMS blocks,
with punctured holes, were aligned and plasma sealed on top of the inlet and outlet ports.6
Silicone tubing was then inserted and epoxy glued into the PDMS inlet and outlet ports.
To complete the fabrication, a lead zirconate titanate piezoelectric transducer (PZT: 5
mm width x 30 mm length x ~1 mm thickness) (Boston Piezo-Optics Inc., Bellingham,
MA) was attached to the bottom side of the chip using cyanoacrylate glue.
Square Glass Microcapillary Acoustofluidic Device
An acoustofluidic device was fabricated out of a borosilicate micro glass square
cell (Friedrich & Dimmock, Inc, Millville, NJ). The device was constructed by gluing a
PZT (5 mm width x 30 mm length x ~ 1 mm thickness) (Boston Piezo-Optics Inc.,
Bellingham, MA) to one of the four flat sides of the square microcapillary using
cyanoacrylate glue. A second PZT can also be glued to the microcapillary to function as a
feedback PZT to ensure that an acoustic standing wave is being generated in the fluidfilled cavity of the acoustofluidic device. To allow easy flow of particle/cell suspensions
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silicone tubing (Cole-Parmer, Vernon Hills, IL) was attached to both ends of the glass
microcapillary. To support the fragile glass microcapillary, the device was mounted on a
glass microslide (Corning Inc., Corning, NY) with crosslinked PDMS cubes that secured
the attachment of the glass microcapillary and raised it approximately 1 cm above the
microslide surface.
Acoustic Focusing and Separation
Samples were flowed (20-100 µL/min) through the acoustofluidic devices using a
microsyringe pump (Nexus 3000, Chemyx Inc. Stafford, TX). To focus and separate
particles and blood cells, the PZT was actuated using a waveform generator (33250A,
Agilent, Santa Clara, CA) at a frequency of 3.101 MHz at 20-50 volts peak-to-peak. To
monitor and image the focusing and separation of particles and blood cells, commercially
available Nile Red (NR)-polystyrene particles (10.2 µm in diameter) (Spherotech Inc.,
Lake Forest, IL) were used, and Nile Red dye (Sigma-Aldrich, St. Louis, MO) was used
to label elastomeric particles and blood cells; this was accomplished by incubation in an
aqueous Nile Red solution (100 µM) in 1 mL of phosphate buffered saline (1X PBS with
7.4 pH: 10 mM Na2HPO4; 1 mM KH2PO4; 138 mM NaCl; 3 mM KCl) for 30 minutes
followed by centrifugal washing (PBS) to remove unbound dye. Focusing and separation
of particles (and blood cells) was monitored and imaged using an epifluorescence
microscope (Zeiss Axio Imager) and a Luca S EMCCD camera (Andor Technology,
Belfast N., Ireland) with Andor imaging software (Andor-Solis).
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Results
Elastomeric Particles (Sylgard 184)
A silicon acoustofluidic device (Figure 5.2A,B) that functions as a 1/2λ resonator
(i.e., 2 pressure antinodes at the side walls and 1 pressure node at the center of the
microchannel) was used to demonstrate the negative acoustic contrast property of
polydisperse elastomeric particles that were synthesized from Sylgard 184 (10:2 ratio of
prepolymer to crosslinking agent). Nile Red (NR)-elastomeric particles (~1.0 x 107
particles/mL) were dispersed while being flowed (20 µL/min) through the acoustic
focusing device with the acoustic field off (Figure 4.3A). Once an ultrasonic acoustic
pressure standing wave field was applied (3.101 MHz at 20 Vpeak-peak), NR-elastomeric
particles were rapidly focused to pressure antinodes at the side walls of the microchannel
(Figure 5.3B). The application of the acoustic pressure standing wave field demonstrated
that elastomeric particles synthesized from Sylgard 184 function as negative acoustic
contrast particle.
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(A)

(B)

PZT

Figure 5.2 Silicon acoustic focusing device that was used for acoustic focusing and
separation. (A) top view and (B) side view showing the actuating PZT coupled to the
silicon acoustic focusing device. Note: The red dashed box indicates where initial
acoustic focusing and separation occurs.

Once elastomeric particles (2.5 x 107 particles/mL) that were synthesized from
Sylgard 184 were shown to possess negative acoustic contrast properties, the application
of acoustically separating them from a high concentration of human blood (10% dilution
in 1X PBS with 0.1% BSA) with continuous flow (20 µL/min) was demonstrated. Upon
application of the acoustic pressure standing wave field (3.101 MHz at 20 Vpeak-peak) the
NR-elastomeric particles were rapidly focused to the pressure antinodes while blood cells
were focused to the pressure node at the center of the microchannel (Figure 5.3C). The
activation of the acoustic pressure standing wave field demonstrated that the separated
elastomeric particles at the pressure antinodes were forming aggregates and experiencing
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a decrease in their flow velocity; the decrease in flow velocity of the focused elastomeric
particles is a result of the applied acoustic forces and the laminar flow profile within the
acoustofluidic device. Though, work needs to be performed in order to understand and
control the aggregation of focused elastomeric particles at pressure antinodes the results
clearly demonstrate that elastomeric particles synthesized from Sylgard 184 (10:2 ratio of
prepolymer to crosslinking agent) function as negative acoustic contrast particles and can
be efficiently separated from human blood using an ultrasonic acoustic standing wave
field within an acoustofluidic device.
Elastomeric Particles (low molecular weight PDMS)
Since previous studies performed in our laboratory have demonstrated efficient
production of monodisperse elastomeric particles using a low molecular weight PDMS, it
became essential to determine their acoustic contrast properties. Polydisperse elastomeric
particles were utilized for proof-of-concept experimentation. A low-cost square glass
microcapillary that functions as a 1/2λ acoustic resonator (Figure 5.4A), was used to
determine the negative acoustic contrast properties of polydisperse elastomeric particles
that were synthesized from a low molecular weight PDMS (1:1 ratio of prepolymer to
crosslinking agent). Elastomeric particles (~ 1.25 x 108 particles/mL) were equally
dispersed with no flow in the acoustofluidic device with the acoustic field off (Figure
5.4B).
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Elastomeric
Particles
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Figure 5.3 Polydisperse elastomeric particles synthesized from Sylgard 184 (10:2 ratio of
prepolymer to crosslinking agent) function as negative acoustic contrast particles and can
be separated from 10% human blood. Nile Red (NR)- Elastomeric particles flowed (20
µL/min) through the acoustic focusing device with the acoustic field (A) off and then (B)
on. (C) A mixture of (NR) elastomeric particles and (NR) human blood (10% dilution in
1X PBS with 0.1% BSA) flowed (20 µL/min) through the silicone-based acoustofluidic
device with the ultrasonic acoustic standing field on.

93
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Field Off
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Figure 5.4 Elastomeric particles synthesized from a low molecular weight PDMS (1:1
ratio of prepolymer to crosslinking agent) are shown to function as negative acoustic
contrast particles using a low-cost glass square microcapillary that functions as an
acoustofluidic device. (A) Image of a square glass microcapillary that has been converted
into an acoustofluidic chip by way of coupling PZTs to the surface. Elastomeric particles
suspended in the microchannel with the field (B) off and then (C) on. Note: Image of the
square glass microcapillary (A) was taken by Menake Piyasena and is used with his
granted permission.
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Once an ultrasonic acoustic pressure standing wave field was applied (3.101 MHz at 50
Vpeak-peak), elastomeric particles were rapidly focused to pressure antinodes at the side
walls of the microchannel; however there does appear to be a particle aggregate at the
pressure antinode along the right side of the microchannel wall (Figure 5.4C). The
focusing of elastomeric particles at the pressure antinodes clearly demonstrates the
negative acoustic contrast properties of elastomeric particles that are synthesized from a
low molecular weight PDMS.
To determine if elastomeric particles synthesized from low molecular weight
PDMS could be separated from positive acoustic contrast particles, elastomeric particles
(~2.5 x 107 particles/mL) were mixed with commercially-available polystyrene particles
(~6.4 x 105 particle/mL) and flowed (100 µL/min) through a square glass microcapillary
acoustofluidic device. The mixture was dispersed while being flowed with the acoustic
field off (Figure 5.5A). Upon activation of the ultrasonic acoustic pressure standing wave
field (3.101 MHz at 50 Vpeak-peak) elastomeric particles rapidly focused to pressure
antinodes while polystyrene particles were focused to the central pressure node of the
microchannel (Figure 5.5B). The activation of the acoustic pressure standing wave field
demonstrated that 1) elastomeric particles synthesized from low molecular weight PDMS
possess negative acoustic contrast properties and can be separated from positive acoustic
contrast particles (polystyrene); and 2) once these elastomeric particles are focused at
pressure antinodes they experience a significant decrease in their flow velocity. These
results indicate that elastomeric particles synthesized from a low molecular weight
PDMS (1:1 ratio of prepolymer to crosslinking agent) function as negative acoustic
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contrast particles and can be separated from positive acoustic contrast particles
(polystyrene particles).

(A)

(B)

Field Off

Elastomeric
Particles

Field On
Polystyrene
Particles

Figure 5.5 Elastomeric particles synthesized from low molecular weight PDMS (1:1 ratio
of prepolymer to crosslinking agent) function acoustically separated from positive
acoustic contrast particles. A mixture of elastomeric particle and polystyrene particles
flowed (100 µL/min) in an acoustofluidic device with the acoustic field (A) off and then
(B) on.
Conclusions and Future Directions
Elastomeric particles that possess negative acoustic contrast properties can be
synthesized from two varieties of PDMS elastomers, Sylgard 184 (specific gravity 1.03)
and a low molecular weight PDMS (specific gravity ~ 0.97). Elastomeric particles
synthesized from Sylgard 184 and low molecular weight PDMS were successfully
separated from positive acoustic contrast particles (blood cells and polystyrene) upon
activation of the ultrasonic acoustic pressure standing field. The negative acoustic
contrast property of PDMS-based elastomeric particles has potential to be used in capture
assays where the capturing of specific analytes is performed on elastomeric capture
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microparticles (ECµPs) in solutions containing particulate matter that functions as
positive acoustic contrast particles (e.g., biological cells, commercially-available particles,
plastics, sand, and metals).1 Upon capturing and concentrating the desired analyte on the
surface of the ECµPs, the application of an ultrasonic acoustic standing wave field could
be used to separate and concentrate ligand-bound ECµPs from background generating
particles that function as positive acoustic contrast particles.2 Once ligand-bound ECµPs
are separated and concentrated at pressure antinodes, and the background generating
particles at pressure nodes, it may be possible to perform on-chip flow cytometry or
collect and remove the concentrated ligand-bound ECµPs from the acoustofluidic device
prior to performing spectroscopic analysis (e.g., flow cytometry, mass spectrometry).2
Acoustic focusing of elastomeric particles at the pressure antinodes along the side
walls of the microchannel has a tendency to form isolated aggregates in the presence of
no flow or reduced flow rates. The generation of these aggregates at pressure antinodes
could have a negative impact on the laminar flow profile within the microchannel, and
thus make it more difficult to flow focused particles into collecting outlet channels (e.g.,
trifurcation). It seems possible that these formed aggregates or clumps at the side walls of
the microchannel maybe caused in part by secondary acoustic forces (Bjerknes attractive
forces). As a result of elastomeric particles (Sylgard 184 and low molecular weight
PDMS) having a density that is similar to their surrounding medium, any secondary
forces experienced by the elastomeric particles would probably be attractive Bjerknes
forces. However, in a video showing the focusing of elastomeric particles synthesized
from low molecular weight PDMS to pressure antinodes, it can be observed with the
acoustic field on (without flow) that elastomeric particles that appear relatively distant
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from the densely populated clumps at the side pressure antinode, appear to be migrating
in the direction of the formed clumps. It also appears that there may be periodic clumping
that is occurring throughout the microchannel. Previous results published by Evander et
al.,7 demonstrated that it was possible to produce an acoustic standing wave down the
length of the microchannel. This result, along with the periodic clumping of elastomeric
particles at the pressure antinodes along the side walls of the microchannel, may be due
in part to an acoustic standing wave that is being propagated down the length of the
microchannel. An experimental method to determine if there is an acoustic standing wave
being propagated down the microchannel is to perform the acoustic focusing of the
elastomeric microparticles multiple times and observe if the elastomeric particle clumps
form at the same positions at the pressure antinodes as previously noted. If the clumps
form at precisely the same position down the entire length of the microchannel, then there
would certainly be an increased probability that an acoustic standing wave was being
propagated down the microchannel.
A reduction of these clumping forces may also be possible by lowering the
voltage applied on the actuating PZT which directly affects the pressure amplitude and
therefore the acoustic forces that are exerted on the particles.3 Another option is to
increase the flow rate to a level that still maintains laminar flow but generates enough
shear forces to overcome these clumping forces that are causing aggregation at the side
walls. A high concentration of particles may also increase the clumping forces that are
generated during the application of the acoustic field.3 Flow rates, voltages applied on
the actuating PZT, and the concentration of the particles can all be experimentally
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controlled to determine if modification to these variables can minimize the amount of
aggregation that is occurring during the activation of an acoustic standing wave field.
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Abstract
This report describes the development of elastomeric capture microparticles (ECµPs) and
their use with acoustophoretic separation to perform microparticle assays via flow
cytometry. We have developed simple methods to form ECµPs by crosslinking droplets
of common commercially available silicone precursors in suspension followed by surface
functionalization with biomolecular recognition reagents. The ECµPs are compressible
particles that exhibit negative acoustic contrast in ultrasound when suspended in aqueous
media, blood serum or diluted blood. In this study, these particles have been
functionalized with antibodies to bind prostate specific antigen and immunoglobulin
(IgG). Specific separation of the ECµPs from blood cells is achieved by flowing them
through a microfluidic acoustophoretic device that uses an ultrasonic standing wave to
align the blood cells, which exhibit positive acoustic contrast, at a node in the acoustic
pressure distribution while aligning the negative acoustic contrast ECµPs at the
antinodes. Laminar flow of the separated particles to downstream collection ports allows
for collection of the separated negative contrast (ECµPs) and positive contrast particles
(cells). Separated ECµPs were analyzed via flow cytometry to demonstrate nanomolar
detection for prostate specific antigen in aqueous buffer and picomolar detection for IgG
in plasma and diluted blood samples. This approach has potential applications in the
development of rapid assays that detect the presence of low concentrations of biomarkers
in a number of biological sample types.
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Introduction
Acoustic microfluidic systems are of significant utility in the analysis and
separation of a number of biological samples, including blood.1-4 Whole blood comprises
45-50% hematocrit (blood cell volume) and a plethora of serum proteins. Many serum
proteins are biomarkers for a number of pathologies, including cancers, inflammatory
responses, and infectious diseases.5-9 Sensitive and rapid quantification of such
biomarkers is very useful for early diagnoses and for monitoring the therapeutic success
of many clinical treatments.10 To detect and quantify low concentrations of serum
biomarkers, it is often necessary to remove blood cells prior to analysis.11 This is most
commonly performed via centrifugation,12,13 which is time consuming, labor intensive,
and requires milliliters of blood. Once the serum protein containing supernatant is
obtained, immunoassays can be performed to detect and quantify low concentrations of
the desired biomarker present in the serum,14,15. Other more specific protein purification
and enrichment methods such as: 2-D gel electrophoresis, chromatography, precipitation
or filtration can also be performed prior to analysis, for example using mass
spectrometry.16-19
Acoustic standing waves offer an alternative to centrifugation for blood cell
separation. Initial work on this approach concentrated blood cells, which generally
exhibit positive acoustic contrast, to nodes in a standing wave where they aggregated and
sedimented out of solution to leave clarified plasma.20 Based on similar acoustic
principles, many acoustophoretic flow through systems have been developed by Laurell
et al. to separate blood cells from serum, lipids, and platelets.21-26 In general this approach
uses flow channels in a rigid substrate to which a acoustic driver (e.g., a PZT crystal) is
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attached to generate a standing acoustic wave across the channel. Drive frequencies are
chosen to match the dimensions of the channel such that the wavelength of the standing
wave has fractional harmonics across the channel (e.g., 1/2l, 3/2l, etc.), which creates
acoustic nodes and antinodes across the channel. Cells are concentrated to the nodes and
separated from the plasma by collecting the focused cells downstream in microfluidic
channels. As described below there is a significant dependence of particle size to the
magnitude of the force imparted on a particle by the standing wave, which allows for size
dependent acoustophoretic fractionation of components such as platelets.25 Of interest
here is the observation that particles exhibiting negative contrast, such as lipids, can be
separated by collecting them as they are driven to the antinode.21,22,23
The primary acoustic force on particles in an acoustic standing wave field can be
calculated from the following equations.22,23,27

F! = −

πp! V! β!
φ β, ρ sin 2kx
2λ

φ β, ρ =

5ρ! − 2ρ! β!
− !!!!!!
2ρ! + ρ!
β!

(1)

(2)

The magnitude of the primary acoustic force is directly proportional to the volume
of the particles (V! ), the pressure amplitude of the field (p! ) the applied frequency (1/λ),
and the acoustic contrast factor  φ β, ρ . The value of the acoustic contrast factor depends
on the density of the particles (ρ! ) and the suspension media (ρ! ) and the
compressibility of the particles (β! ) and the suspension media (β! ). If φ β, ρ   has a
positive value then the acoustic field will exert a time-averaged force moving particles to
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the acoustic pressure node of a standing wave (positive contrast particles). However, if
φ β, ρ   has a negative value then the acoustic field will exert a time-averaged force
moving particles to acoustic pressure antinodes in a standing wave (negative contrast
particles). A more detailed description of the acoustic forces exerted on particles under an
acoustic standing wave field can be found in Bruus et al.28
In this report we demonstrate facile synthesis of elastomeric particles from a
common water insoluble elastomer, crosslinked polydimethylsiloxane (Dow Corning
Sylgard 184), which we hypothesized would (i) exhibit negative acoustic contrast, and
thus (ii) allow their continuous separation from blood cells in an acoustic microfluidic
chip. We introduce the concept of negative contrast elastomeric capture microparticles
(ECµPs) and demonstrate the use of ECµPs in model antigen and antibody capture assays
conducted in buffer, plasma and diluted whole blood in an acoustic sample preparation
chip. As ECµPs are separated continuously from blood cells they are collected into
fractions, which are then analyzed using flow cytometry.29 This continuous separation of
ECµPs via acoustophoresis has the potential to greatly simplify immunoassays by
obviating the need for centrifugation and lysis steps that are normally used to remove the
background generating blood cells that are present at 5x109 cells per mL. Finally, simple
and rapid separations, such as acoustophoretic ECµPs displaying high affinity antibodies,
have the potential to improve the sensitivity of detection for biomarkers by reducing the
number of sample preparation steps that can lead to non-specific loss of biomarkers of
interest. 30 This analysis could be performed directly on ECµPs (e.g., through particle
based immunoassays and flow cytometric detections) or through other subsequent
analysis methods (e.g., mass spectrometry) on separated ECµPs.
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Materials and Methods
Acoustic Focusing and Separation
Samples were flowed (45 µL/min) through the acoustic sample preparation chip
(see supplementary information (SI) for details of fabrication of the chip) using a
microsyringe pump (Nexus 3000, Chemyx Inc. Stafford, TX). To focus and separate
particles and blood cells, the PZT was actuated using a waveform generator (33250A,
Agilent, Santa Clara, CA) at a frequency of 2.91 MHz at 10 volts peak-to-peak. To
monitor and image the focusing and separation of particles and blood cells, commercially
available Nile Red (NR)-polystyrene particles (PS) (Spherotech Inc., Lake Forest, IL)
were used, and Nile Red dye (Sigma-Aldrich, St. Louis, MO) was used to label
elastomeric particles and blood cells; this was accomplished by incubation in an aqueous
Nile Red solution (100 µM) in 1 mL of phosphate buffered saline (1X PBS with 7.4 pH:
10 mM Na2HPO4; 1 mM KH2PO4; 138 mM NaCl; 3 mM KCl) for 30 minutes followed
by centrifugal washing (PBS) to remove unbound dye. Focusing and separation of
particles (and blood cells) was monitored and imaged using an epifluorescence
microscope (Zeiss Axio Imager) and a Luca S EMCCD camera (Andor Technology,
Belfast N., Ireland) with Andor imaging software (Andor-Solis). This software was used
to perform intensity analysis of line scans across the width of the microchannel. The
average of 17 scans from bottom to top was used to generate fluorescence histograms
using PRISM® software (version 5.0b, GraphPad).
Synthesis of Elastomeric Particles
Sylgard 184 (1 g, 10:2 ratio of PDMS prepolymer to crosslinking agent) (Dow
Corning Corp., Midland, MI) was emulsified in 10 mL of ultrapure water (18.2 MΩ•cm
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@ 25 °C; Synergy®, EMD Millipore), using a homogenizer (Power Gen 125, Fisher
Scientific) set at 6K RPM for ~ 60 seconds. The droplets were cured at 100 °C for ~ 1
hour to form crosslinked elastomeric particles. Elastomeric particles were imaged using
bright field microscopy (BH-2, Olympus) and a 4300 cool pix camera (Nikon). The scale
bar was calibrated based on standardized monodisperse particles (mean = 30.1 µm;
standard deviation = ± 2.1 µm; and a coefficient of variation = 6.6%) (Thermo
Scientific). A Coulter counter (Z2 Coulter Particle Count and Size Analyzer, Becton
Dickinson) was used to determine the concentration and the size distribution of the
polydisperse elastomeric particles.
Biofunctionalization of Polydisperse Elastomeric Particles
Elastomeric particles (2.5 x 107) where incubated in 1 µM avidin (Molecular
Probes, Eugene, Oregon) in PBS for 30 minutes with continuous rocking at room
temperature. They were then centrifugally (2900 g for 5 minutes) washed and
resuspended in washing/blocking buffer (PBS with 0.1 % BSA). A biotinylated mouse
anti-human prostate specific antigen (PSA) monoclonal antibody (capture antibody;
HyTest Ltd., Turku, Finland; catalog # 4P33B Mab8A6; lot # 10/11-P33B-8A6) was
added to make a 6 nM solution; the solution was incubated for 30 minutes with rocking at
room temperature. The resulting ECµPs were centrifugally washed and resuspended in
the washing/blocking buffer.
Separation Efficiency Measurements
1.5 x 105 ECµPs were fluorescently labeled with a goat anti-mouse antibody (PE)
and mixed with 0.1% porcine whole blood in 200 µL of total volume (diluted in PBS
with 0.1% BSA). The initial fraction of ligand-bound ECµPs to porcine blood cells was
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determined based on flow cytometry gating ((fluorescence (585 ± 20 nm) vs. forward
side scatter). The mixture was then flowed (45 µL/min) through the acoustic sample
preparation chip with the acoustic field on (2.91 MHz at 10 Volts peak-to-peak) and the 3
separated fractions at the trifurcation were collected through the outlet silicone tubing.
Once collected, the fractions were analyzed in an Accuri C6 flow cytometer where gating
was performed, as mentioned-above, to determine the percentages of ligand-bound
ECµPs and porcine blood cells in each of the collected fractions.
Preparation of Plasma
1 mL samples of whole porcine blood containing sodium heparin
(Bioreclamation) were centrifuged in 1.7 mL polypropylene microcentrifuge tubes using
a Galaxy 14D microcentrifuge (VWR, Radnor, PA) at 2000 g for 10 minutes. Supernatant
(plasma) was carefully pipetted into microcentrifuge tubes and stored in 0.5 mL aliquots
at -20 °C.
PSA Titration in Physiological buffer
5 x 105 ECµPs –elastomeric particles functionalized with mouse anti-human PSA
monoclonal antibodies (HyTest Inc., Turku, Finland)– were incubated with different
concentrations (0, 1, 5, 10, 20, 30 nM) of prostate specific antigen (PSA) (Meridian Life
Sciences Inc., Memphis, TN) in 200 µL of washing/blocking buffer for 30 minutes with
continuous rocking at room temperature. Without washing, enough mouse anti-human
PSA monoclonal antibody-FITC (detection antibody) (HyTest Inc., Turku, Finland) was
added to make a 1 nM solution that was incubated for 30 minutes with rocking at room
temperature. The ECµPs were then analyzed with an Accuri C6 flow cytometer without
washing. All bioassay data was fitted to a one-site binding curve with the following
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equation, 𝑌 =

!!"# ∗!
!! !!

using PRISM (Graph Pad) version 5.0b. The dependent variable (Y)

is the median fluorescence intensity (MFI, y-axis), the independent variable (x) is the
ligand analyte concentration (x-axis), Kd is the dissociation constant and Fmax is the
maximum MFI.
IgG-PE Titration in 10% Plasma
5 x 105 ECµPs –elastomeric particles functionalized with mouse anti-human PSA
monoclonal antibodies (Abcam, Cambridge MA)– were incubated with different
concentrations, (0, 21, 42, 84, 168, 336, 672 pM) of goat anti-mouse IgG-phycoerythrin
(PE) (Abcam, Cambridge MA) in 200 µL of 10% volume porcine plasma (diluted in the
washing/blocking buffer) for 30 minutes with continuous rocking at room temperature.
ECµPs were then analyzed in an Accuri C6 flow cytometer without prior washing.
Titration in 0.1% Blood, Acoustic Separation, and Flow Cytometry
ECµPs –again, elastomeric particles (5 x 105) functionalized with mouse antihuman PSA monoclonal antibodies– were incubated with different concentrations (0, 21,
42, 84, 168, 336, 672 pM) of goat anti mouse IgG-(PE) (Abcam, Cambridge MA) in 200
µL of 0.1 % volume whole porcine blood (porcine blood was diluted in washing/blocking
buffer) for 30 minutes with continuous rocking at room temperature. Samples were then
flowed (45 µL/min) through the acoustic sample preparation chip with the acoustic field
on (2.91 MHz; 10 V peak-to-peak supplied to the PZT) and collected through the outlet
silicone tubings. Once collected, ligand-bound ECµPs were analyzed in an Accuri C6
flow cytometer without prior washing.
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Flow Cytometry Gating in Bioassays
Flow cytometry (Accuri C6) data on ECµPs was acquired by gating on forward
and side scatter parameters to exclude debris and doublets. The median fluorescence
intensity of gated ECµPs was used to formulate the binding curves shown within the
manuscript.
RESULTS
Particle Separation Approach
Particles (or cells) with different acoustic contrast properties can be focused (i.e.,
acoustically positioned to nodal or antinodal planes) and then separated using an acoustic
sample preparation chip with a downstream trifurcation (Figure 6.1a) (see SI Figure S6.1
for an image of an actual acoustic sample preparation chip).22 After acoustic focusing,
laminar flow carries particles continuously into outlet channels at the trifurcation for
collection (Figure 6.1a). The attached acoustic transducer (PZT) has an appropriate size
to allow resonance at the frequency (2.91 MHz) that corresponds to a wavelength that is
twice the width (252 µm) of the acoustic focusing channel (Figure 6.1b). Thus a resonant
acoustic standing wave is established in the fluid-filled cavity of the chip and the field
exerts a time-averaged force that focuses positive contrast particles (e.g., blood cells) to
the center pressure node and negative contrast particles (e.g., elastomeric particles) to the
two pressure antinodes at the sides of the channel (Figure 6.1b).21,22
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Figure 6.1 (a) Schematic diagram depicting the separation approach for elastomeric
negative acoustic contrast particles (white) from positive acoustic contrast particles (e.g.,
blood cells) (black) at the trifurcation in a silicon acoustic sample preparation chip. (b)
Cross-section, at dashed line in (a), of the chip, with the positive contrast particles
focused at the pressure node and the negative contrast particles focused at the pressure
antinodes under an acoustic standing wave field. Note: Images are not drawn to scale. (c)
Bright field image and size histogram of PDMS-based elastomeric particles prepared by
bulk emulsification.
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Particle Synthesis
Polydisperse elastomeric particles were synthesized using an oil-in-water bulk
emulsion process without the use of detergent. The synthesis method is straightforward
and allows polydisperse elastomeric particles to be rapidly synthesized (~1 hour) with a
bulk concentration of 1.3 x 108 particles/mL. The diameters of particles produced by this
method varied from submicron to approximately 21 µm in diameter (Figure 6.1c). As
prepared, these particles were unstable in regards to particle aggregation; adsorption of
avidin allowed the elastomeric particles to maintain stability during centrifugal washes
(2900 g for 5 minutes) performed in a washing/blocking buffer.
Acoustic Focusing and Separation
Acoustic focusing experiments were performed on Nile Red labeled ECµPs (NRECµPs) to examine their acoustic contrast properties and the optimal operating conditions
of the acoustic sample preparation chip (e.g., particle concentrations, flow rates,
resonance frequency, and applied voltage on the actuating PZT). The field of view of the
epifluorescence microscopic objective (2.5x, NA of 0.3) was large enough to capture the
entire width (252 µm) of the central micro-channel in the acoustic sample preparation
chip and was positioned to capture fluorescent images in the central micro-channel
upstream of the trifurcation. NR-ECµPs (2.5 x 107 particle/mL) were flowed (45 µL/min)
continuously through the acoustic sample preparation chip with the acoustic field off
(Figure 6.2a) and then on (Figure 6.2b); the concomitant increase in Nile Red
fluorescence at the sides of the micro-channel, indicated an increase in the concentration
of NR-ECµPs at the pressure antinodes. Histograms of the average fluorescence intensity
measured across the channel width confirm the relatively uniform distribution of
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fluorescence particles across the channel width in the absence of the acoustic field
(Figure 6.2a), and the focusing of the NR-ECµPs at the side-walls of the channels upon
imposition of the acoustic field (Figure 6.2b). The NR-ECµPs thus exhibit negative
acoustic contrast and are focused to the pressure antinodes along the sides of the microchannel walls upon imposition of a resonant frequency (2.91 MHz) to the acoustic sample
preparation chip.
To evaluate the ability of ECµPs to be acoustically separated from positive
contrast particles and the ability of the acoustic sample preparation chip to support
effective separations, NR-ECµPs (2.5 x 107 particles/mL) were separated from positive
contrast, Nile Red labeled polystyrene particles (NR-PS: 2.5 x 106 particles/mL) (Figure
6.2c). Further, to demonstrate that ECµPs could be continuously separated from blood
cells NR-ECµPs (2.5 x 107 particles/mL) were separated from Nile Red stained blood
cells (NR-blood cells: 0.1% volume whole porcine blood) (Figure 6.2d) using the same
acoustic set-up described above.
Separation at Trifurcation
As a result of laminar flow within the micro-channel (Re = 7.4), acoustically
focused ECµPs flow directly into the peripheral outlet channels at the trifurcation for
collection. NR-ECµPs (2.5 x 107 particles/mL) were continuously flowed (45 µL/min)
through the acoustic sample preparation chip. Figure 4.3 shows images at the trifurcation,
with the field off (Figure 6.3a) and then on (Figure 6.3b); the concomitant increase in
Nile Red fluorescence at the sidewalls of the side outlet channels of the trifurcation
demonstrated that ECµPs were acoustically manipulated into side outlet channels for
continuous collection.
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Figure 6.2 ECµPs function as negative contrast particles and can be separated from
positive contrast particles using an acoustic sample preparation chip. These images were
captured via an epifluorescence microscope with a 2.5x objective. Each sample was
flowing at 45 µL/min. Fluorescence microscopy images along with histograms of average
intensity profiles for Nile Red (NR) stained ECµPs with the field (a) off and then (b) on.
(c) NR-ECµPs separated from NR-PS particles with the field on. (d) NR-ECµPs
separated from NR-blood cells with the field on. Note: white dashed lines in (a) indicate
micro-channel borders.
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Figure 6.3 (a) Fluorescence microscopy images of NR-ECµPs with the field (a) off and
then (b) on. (c) NR-ECµPs separated from NR-PS particles with the field on. (d) NRECµPs separated from NR-blood cells (0.1% volume whole porcine blood) with the field
on. Each sample was flowing at 45 µL/min. Note: white dashed lines indicate microchannel borders that are not otherwise visible due to presence of NR-ECµPs.
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To evaluate whether ECµPs can be separated, concentrated, and collected apart from
positive contrast particles, polydisperse NR-ECµPs (2.5 x 107 particles/mL) were
continuously separated from NR-PS particles (2.5 x 106 particle/mL) at the trifurcation
(Figure 6.3c). Laminar flow also allowed acoustically focused and separated NR-ECµPs
and NR-blood cells (from 0.1% porcine whole blood) to maintain focusing and allow
shunting into designated outlet channels at the trifurcation for collection. Focused NRECµPs flowed into side outlet channels and NR-blood cells flowed directly into the
center outlet channel at the trifurcation (Figure 6.3d).
ECµPs used in Bioassays
Biospecific Functionalization of Negative Contrast Particles
Biofunctionalization of elastomeric particles was accomplished by nonspecifically adsorbing avidin to the hydrophobic surface of the elastomeric particles. To
demonstrate their specific biotin-binding ability, avidinylated elastomeric particles were
titrated with biotin-4-fluorescein; controls were performed where avidinylated
elastomeric particles were pre-incubated with free biotin (biotin-block) followed by
incubation with biotin-4-fluorescein (see SI Figure S6.2). Our results indicate that (i)
avidin protein can be non-specifically adsorbed to bare elastomeric particles, and (ii)
adsorbed avidin protein maintains biotin-binding functionality and binds biotin with
minimal non-specific adsorption. Once elastomeric particles have been functionalized
with avidin they can be further functionalized with a biotinylated capture antibody (see SI
Figure S6.3). These results demonstrate that negative contrast elastomeric particles can
be biofunctionalized using simple avidin/biotin conjugation reagents.
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PSA Sandwich Assays Performed in Physiological Buffer
ECµPs were used in a titration assay for prostate specific antigen (PSA) in PBS
(0.1 % BSA) in which anti-human PSA monoclonal antibody-FITC was used as the
secondary (detection) antibody in a sandwich assay configuration. The assay data
exhibited high signal-to-noise (Figure 6.4a) and very low background indicative of
biospecific analysis and were fit to a one-site binding curve (R2=0.89) where saturation
was approached near 30 nM PSA. To estimate the limit of detection (LOD) for this
analysis, a propagation of errors model was used as described by Long and
Winefordner.31 First, the standard deviation of the blank samples (SB) was determined
(𝑆! = 1568;   𝑛 = 3). Next, a line was fit to points from triplicate determinations that
represented the most linear region of the binding curve (PSA concentrations: 0, 1, and 5
nM PSA). The best fit for a straight line was calculated by non-linear regression to a
straight line model using PRISM version 5.0 software (GraphPad). Calculated best fit
values included the slope (m = 2903) and MFI axis intercept (i= 3706) of the line as well
as standard errors for each (Sm = 1605 and Si = 4724, respectively). These values were

used to calculate LOD using the equation 𝐿𝑂𝐷 =   
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in which k =3, the

number of standard deviations of separation between two points that equaled a 99%
probability of being different. The LOD was calculated to be approximately 6 nM.
IgG-PE Binding Assays Performed in 10% Porcine Plasma
To examine biospecific binding of ECµPs in a complex solution of proteins, an
IgG capture assay was performed in 10% whole porcine plasma (diluted with 0.1% BSA
in PBS). ECµPs were used in a titration binding assay for a polyclonal goat anti-mouse
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IgG-phycoerythrin (PE). The standard assay data exhibited high signal-to-noise (Figure
6.4b) and very low background indicative of biospecific adsorption and were fitted to a
one-site binding curve. This fit well (R2=0.99) but provided a linear response implying
that we did not achieve saturation over our titration range. The calculated LOD using
propagation of errors (𝑘 =   3;  𝑆! = 16;  𝑆! =   237.5;  𝑆! =   0.8145;   𝑚 =   47.75;   𝑖 =
  454.6) for all 6 points (0, 21, 42, 187, 334, 668 pM IgG-PE) on the binding curve, was
calculated to be approximately 15 pM.

Figure 6.4 ECµPs as platforms for protein capture assays in flow cytometry. Note: ( )
denotes ECµPs with capture antibody and ( ) denotes particles without capture
antibody. (a) ECµPs used in a sandwich assay for prostate specific antigen (PSA) in
physiological buffer (PBS). (b) ECµPs used in a binding assay for goat anti-mouse IgGphycoerythrin performed in 10% volume porcine plasma diluted with PBS. Note: all data
points were obtained from triplicate experiments analyzed by gated flow cytometric
analysis. Error bars represent the standard deviation of the mean for 3 separate
determinations of median fluorescence intensity.

118

ECµPs and Blood Cells Collected from Trifurcation
Ligand-bound ECµPs (Ligand = goat anti mouse IgG antibody-PE) were
separated from porcine blood cells using an acoustic sample preparation chip. To
determine the effectiveness of separating ECµPs from blood cells, separation efficiency
measurements were performed by analysis via flow cytometry of fractions collected from
each leg of a trifurcation. Control experiments (see SI Figure S6.4) were performed to
determine gating regions in flow cytometry scatter plots (fluorescence (585 ± 20 nm)
versus forward scatter) that allow identification and quantitation of ligand-bound ECµPs
and blood cells. A mixture (73% blood cells; 27% ligand-bound ECµPs, Figure 6.5a) was
prepared and then flowed through the acoustic sample preparation chip with the acoustic
field on. The outputs from the two peripheral outlet channels were collected and
consisted mostly of ligand-bound ECµPs (95-96% ligand-bound ECµPs, 4-5% blood
cells; see Figures 6.5b,d); whereas the output from the central outlet channel consisted
mostly of blood cells (98% blood cells, 2% ligand-bound ECµPs; see Figure 6.5c). Our
results thus indicate that ligand-bound ECµPs can be efficiently separated away from
blood cells using an acoustic sample preparation chip with a downstream trifurcation.
IgG-PE Binding Performed in 0.1% Blood with Acoustic Separation Prior to Assay
ECµPs were used in an IgG-PE assay in which IgG capture was performed in 0.1
% porcine blood prior to separation from blood cells, collection of the ECµPs using an
acoustic sample preparation chip, and their subsequent analysis via flow cytometry. The
blood was diluted to 0.1% (or 5 x 106 cells/ml) to eliminate acoustic scattering from cells
that is known to occur in whole or high concentration blood.32 High concentrations of
red cells under an acoustic standing wave field can generate acoustic scattering that
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results in secondary acoustic forces (i.e., interparticle forces on red cells).32 These
secondary acoustic forces can cause red cells to aggregate or experience repulsive
forces,32 and thus result in decreased focusing and lower separation efficiencies. Future
work will examine the maximum concentration of blood that can be used in conjunction
with ECµPs. Nonetheless, the blood concentrations used are consistent with those used in
ELISA assays.33 The assay data exhibited high signal-to-noise and very low background
indicative of biospecific binding and were fit to a one-site binding curve (R2=0.99) where
we had a near linear response implying that we did not reach saturation over our titration
range (Figure 6.5e). The calculated LOD using propagation of errors (𝑘 =   3;  𝑆! =
184;  𝑆! =   424.4;  𝑆! =   1.456;   𝑚 =   21.53;   𝑖 =   513.3) for all 6 points (0, 21, 42,
187, 334, 668 pM IgG-PE) on the binding curve, was calculated to be approximately 65
pM.
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Figure 6.5 ECµPs used in an assay in diluted blood where acoustic separation and
collection was achieved using the acoustic sample preparation chip prior to flow
cytometry analysis. (a) Flow cytometry scatter plot (forward scatter versus fluorescence
(585 ± 20 nm)) showing the initial mixture (inlet) of ligand-bound ECµPs and blood
cells. (b) Scatter plot of the collected fraction of the left peripheral outlet channel. (c)
Scatter plot of the collected fraction from the central outlet channel. (d) Scatter plot of the
collected fraction of the right peripheral outlet channel. (e) IgG-PE binding assay in 0.1
% porcine blood from ECµPs separated and collected using an acoustic sample
preparation chip, prior to flow cytometry analysis. ( ) denotes ECµPs with capture
antibody and ( ) denotes particles without capture antibody. Note: all data points were
obtained in triplicate. Error bars represent the standard deviation of the mean for 3
separate determinations of median fluorescence intensity.
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Discussion
We have synthesized PDMS-based ECµPs that possess negative acoustic contrast
and specific biorecognition properties. We have demonstrated that ECµPs enable binding
and acoustophoretic separation of ligand analytes from complex biological samples (e.g.,
blood) containing large concentrations of cells. Furthermore, we have demonstrated that
when the separated ECµPs are analyzed via flow cytometry, highly sensitivity and
selective detection of serum proteins is possible.
Sylgard 184TM and PDMS-based elastomers, in general, are water insoluble
elastomers whose compressibility (inverse of bulk modulus) can be adjusted based on the
amount of crosslinking agent added.34 To date, we have only used Sylgard 184™ based
elastomeric microparticles that were synthesized using standard PDMS prepolymer to
crosslinking agent ratios of 10:1 and 10:2;35 both samples exhibited negative acoustic
contrast. Incorporating other amounts, i.e., increasing or decreasing the amount of
crosslinking agent, may allow adjustments to be made in how elastomeric microparticles
respond to acoustic radiation fields. Other compressible water-insoluble elastomers such
as other silicones, natural rubbers, polyurethanes, butyl rubbers, polybutadienes, styrene
butadienes, fluoroelastomers, polyether block amides, ethylene-vinyl acetates, and
polyacrylic rubber36, have the potential to be synthesized into negative contrast particles
using emulsion-based methodologies such as those employed herein.
The acoustic separation of ligand-bound ECµPs s from blood cells in the acoustic
sample preparation chip occurs rapidly, within seconds or less, and occurs with
continuous flow. The acoustic sample preparation chip allows for ligand-bound ECµPs to
be rapidly collected without (i) performing time-consuming centrifugal washes to remove
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blood cells, and (ii) without other time-consuming protein isolation steps such as 2-D gel
electrophoresis or other protein separation steps (e.g., precipitation, chromatography,
filtering) that are performed prior to mass spectrometry analysis. The use of flow
cytometry, as compared to other detection methods of analysis (e.g., ELISA,
spectrofluorimetry), is advantageous in that it allows ECµPs to be used in homogeneous
(no wash) blood-based assays where unbound fluorescently labeled ligands provide
minimal background.37
The PSA assay was conducted in PBS buffer, and was primarily used to
demonstrate that ECµPs can be used as platforms for binding of medically-relevant
antigens. We note that the PSA concentration range tested was not in the diagnosticallyrelevant range (4 - 10 ng/mL).38 However, our lowest PSA concentration (1 nM) was
detected with a high signal-to-noise ratio and thus shows potential to detect PSA at even
lower concentrations. Future work will emphasize the use of optimal antibodies and
fluorophores for such assays to further improve limits of detection. Furthermore, the use
of monodisperse elastomeric microparticles may provide greater potential to optimize the
functionalization of ECµPs; thus enabling detection of PSA at lower concentration levels.
The ability to bind ligands specifically in the presence of abundant serum proteins
is a necessary component of accurate and sensitive immunoassay platforms for the
detection of low concentration levels of biomarkers in blood. Our detection of 21 pM
IgG-PE (~3 ng/mL) in blood-based samples (Figures 6.4b and 6.5e) is commensurate
with the clinically relevant detection limits for other biomarkers commonly detected in
diagnostics using blood-based samples.38 Furthermore, the continuous flow format of
acoustophoresis will make it possible to couple this approach directly to a conventional
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flow cytometer or to perform cytometry directly on the focused streams as has been done
in other microfluidic systems.4,39
We present the first demonstration of engineered particles with negative contrast
in acoustic based microfluidic bioanalytical systems. The negative contrast property of
ECµPs, along with the use of acoustic sample preparation microfluidic systems have the
potential to enable the development of bioassay systems where the acoustic sample
preparation chip is coupled directly to a flow cytometer. The continuous feed of separated
ligand-bound ECµPs directly into a flow cytometer may allow for a significantly
decreased time-to-analysis along with increased analysis rates. Further improvements
could use ECµPs in portable systems where a disposable acoustic flow cell is used to
separate ECµPs from blood cells before analysis by a low cost flow cytometer.4,39 In
pursuit of making ligand-bound ECµP measurements more accurate and sensitive using
flow cytometry, we are developing methods (such as those based on microfluidics, see SI
Figure S6.5) to synthesize monodisperse elastomeric particles. Such monodisperse
particles would be simpler to identify in flow cytometry as discreet populations with
consistent optical properties. Furthermore, their singular size would make their time
dependent movement in an acoustic standing waves more predictable and simplify
efficient separations using ECµPs.
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Silicon Acoustic Sample Preparation Chip
An acoustic sample preparation chip was fabricated in silicon via
photolithography using a photomask designed from AutoCAD software (Autodesk Inc.,
San Rafael, CA) and a deep reactive ion etching (DRIE) using a protocol described by
Suthanthiraraj et al.1 DRIE allowed specific micro-channel patterns to be etched onto the
surface of the silicon wafer (WaferNet Inc., San Jose, CA). A borosilicate glass slide
(Borofloat 33, Schott North America, Inc., Elms Ford, NY) with 1 mm holes drilled
through it to accommodate inlet and outlet ports (tube connection sites) was then sealed
on top of the etched silicon wafer using anodic bonding.1 To allow easy insertion of
silicone tubing (Cole-Parmer Instrument Company, Vernon Hills IL) into inlet and outlet
ports, square PDMS blocks, with punctured holes, were aligned and plasma sealed on top
of the inlet and outlet ports.2 Silicone tubing was then inserted and epoxy glued into the
PDMS inlet and outlet ports. To complete the fabrication, a lead zirconate titanate
piezoelectric transducer (PZT: 5 mm width x 30 mm length x ~1 mm thickness) (Boston
Piezo-Optics Inc., Bellingham, MA) was attached to the bottom side of the chip using
cyanoacrylate glue.
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Flow
Figure S6.1 Acoustic sample preparation chip.
1. Austin Suthanthiraraj, P. P.; Piyasena, M. E.; Woods, T. A.; Naivar, M. A.; Lopez,
G. P.; Graves, S. W., One-dimensional acoustic standing waves in rectangular channels
for flow cytometry. Methods 2012, 57 (3), 259-271.
2. Saarela,V.; Franssila, S.; Tuomikoski, S.; Marttila, S.; Östman, P.; Sikanen, T.;
Kotiaho, T.; Kostiainen, R., Re-usable multi-inlet PDMS fluidic connector. Sensors and
Actuators B: Chemical 2006, 114 (1), 552-557.
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Avidin Adsorption and Biotin-Binding
Elastomeric particles (2.5 x 107) where incubated in 1 µM avidin (Molecular
Probes, Eugene, Oregon) in 1 mL of phosphate buffered saline (1X PBS with 7.4 pH: 10
mM Na2HPO4; 1 mM KH2PO4; 138 mM NaCl; 3 mM KCl) for 30 minutes with
continuous rocking at room temperature. They were then centrifugally (2900 g for 5
min) washed and resuspended in 1 mL of washing/blocking buffer (0.1 % BSA in PBS)
and incubated with continuous rocking at room temperature for 30 minutes. 5.0 x 105
avidinylated-elastomeric particles were then incubated in 200 µL in PBS with different
concentrations of biotin-4-fluorescein (0, 0.1, 1, 10, 100 nM; Invitrogen) for 30 minutes
with continuous rocking at room temperature. The particles were then analyzed with an
Accuri C6 flow cytometer without prior washing. The biotin-block controls were
performed in a similar manner but were incubated with 400 µM of free-biotin (Sigma-

MFI

Aldrich) prior to incubation with biotin-4-fluorescein.

- Biotin block
+ Biotin block

Biotin-4-Fluorescien (nM)
Figure S6.2 Binding curve for avidinylated-elastomeric particles that were incubated
with different concentrations of biotin-4-fluorescein and then analyzed using flow
cytometry (Accuri C6). The data were fit to a 1-site binding model (R2= 0.99) using
GraphPad PRISM 6.
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Attachment of Biotinylated Capture Antibody
Avidinylated-elastomeric particles (2.5 x 107) were prepared as described above.
A biotinylated mouse anti-human PSA monoclonal antibody (capture antibody) (HyTest
Ltd., Turku, Finland) was added to make a 6 nM antibody solution in 1 mL of PBS,
which was then incubated for 30 minutes with rocking at room temperature. The resulting
ECµPs were centrifugally washed and resuspended in washing/blocking buffer. 5.0 x 105
ECµPs were then incubated in 200 µL of 1 nM of goat anti-mouse IgG-phycoerythrin
(PE) (detection antibody) (Abcam, Cambridge MA) for 30 minutes with rocking at room
temperature. Ligand-bound ECµPs were then analyzed by flow cytometry with a 585 ±
20 nm bandpass filter without prior washing. To determine the level of non-specific
binding of the detection antibody, a negative control was performed in the same way, but
without the inclusion of the biotinylated capture antibody.
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Figure S6.3 Fluorescence histograms showing the attachment of a biotinylated mouse
anti human PSA monoclonal antibody (capture antibody) to avidinylated-elastomeric
particles as measured by flow cytometry. Attachment of the biotinylated capture antibody
was detected using a goat anti mouse polyclonal antibody-PE (detection antibody) (blue
trace). To determine the non-specific binding of the detection antibody, a negative control
(red trace) was performed in the same way, but without the inclusion of the biotinylated
capture antibody. The median fluorescence intensity (MFI) of the negative control was
148, whereas the MFI of the sample treated with the biotinylated capture antibody was
39,270. These results indicate that ECµPs can be easily formed through the specific
adsorption of high molecular weight biotinylated biomolecules (e.g., ~150,000 Da IgGs)
to avidinylated PDMS microparticles.
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Gating of Flow Cytometry Data for Quantifying Separation Efficiency
To identify the blood cell population in subsequent measurements of separation
efficiency, 0.1 % whole porcine blood (diluted in PBS with 0.1% BSA) in 100 µL was
analyzed using flow cytometry (Accuri C6). The data collected from this analysis was
graphed on a scatter plot (fluorescence (585 ± 20 nm) vs. forward scatter, see Fig. S4a).
The above-mentioned blood sample was then diluted into 900 µL of a common lysing
buffer (recipe from Cold Spring Harbor Laboratory: 155 mM NH4Cl; 12 mM NaHCO3;
and 0.1 mM EDTA in DI water) and incubated for 10 minutes at room temperature. The
blood sample was then also analyzed using flow cytometry under identical conditions as
mentioned-above. Based on the two analyses a gate was set to count particles with the
fluorescence and scatter characteristics of blood cells (see Fig. S4a,b).
5.0 x 105 ligand-bound ECµPs (fluorescently labeled ligand = goat anti mouse
IgG antibody conjugated to phycoerythrin, 1 nM) in 200 µL of PBS (0.1% BSA) were
analyzed using flow cytometry. The fluorescence (585 ± 20 nm) vs. forward scatter for
the ECµPs is given in Fig. S4c. The ligand-bound ECµP population was clearly distinct
using these parameters from the blood cell population and thus the gating shown in Fig.
S4 for each population can be used to distinguish each type of particle and to quantify
separation efficiency.
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Figure S6.4 Porcine blood cells and ligand-bound ECµPs were identified using flow
cytometry scatter plots (fluorescence (585±20 nm) vs. forward scatter). To quantify blood
cells and ligand-bound ECµPs (fluorescently labeled ligand = goat anti mouse IgG
antibody conjugated to phycoerythrin) it was necessary to determine the location of the
blood cells and ligand-bound ECµPs on the scatter plots. 0.1% whole porcine blood was
(a) analyzed using flow cytometry followed by lysis (b) and then re-analysis. (c) Ligandbound ECµPs were analyzed using flow cytometry to determine the location of their
appropriate gate. The numbers reported in the plots indicate the fraction of particles
within the gating region in each case.
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Synthesis of Monodisperse Elastomeric Particles
Sylgard 184 (20% crosslinking agent) was used to form microdroplets in a Tjunction microfluidic chip (polydimethylsiloxane-based).1 The continuous phase
contained ultrapure water with 5% polyvinyl alcohol (PVA).2 To prevent Sylgard 184
(with crosslinking agent) from wetting the micro-channel walls, the continuous phase was
first injected using a syringe pump (Nexus 3000, Chemyx Inc. Stafford, TX) at a flow
rate of 5 µL/min. The dispersed phase (Sylgard 184 with 20 wt.% crosslinking agent) was
then injected into the microfluidic chip at a flow rate of 0.08 µL/min. Monodisperse
elastomeric droplets were collected and cured at 70 °C overnight, with stirring, to form
crosslinked monodisperse elastomeric particles. A Coulter counter (Z2 Coulter Particle
Count and Size Analyzer, Becton Dickinson, Franklin Lakes, NJ) was used to determine
the size distribution of the near-monodisperse elastomeric particles.
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Figure S6.5 Uniformly sized elastomeric particles were synthesized using a T-Junction
PDMS microfluidic chip. The mean diameter was measured to be 16.1 µm with a
standard deviation (S.D.) of ± 0.9 µm and a coefficient of variation (C.V.) of 5.6 %.
1. Xu, J.; Li, S.; Tan, J.; Wang, Y.; Luo, G., Preparation of highly monodisperse
droplet in a T‐junction microfluidic device. AIChE journal 2006, 52 (9), 3005-3010.
2. Elbert, D. L.; Hubbell, J. A., Surface treatments of polymers for biocompatibility.
Annual Review of Materials Science 1996, 26 (1).
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Chapter 7 Conclusions and Future Directions
Particle Synthesis
Elastomeric negative acoustic contrast particles can be synthesized using PDMSbased elastomers, Sylgard 184 (specific gravity ~ 1.03) and low molecular weight PDMS
(specific gravity ~ 0.97) using a bulk emulsion process and PDMS-based microfluidic
systems, e.g., T-junction and flow focusing configurations. The elastomeric particles that
are synthesized using the bulk-emulsion process (with or without surfactants) are
polydisperse in size (submicron to a approximately 21µm in diameter) and can be
produced rapidly (~ 1 hour) at high concentration levels ( ~1.25 x 108 particles/mL).
The production of PDMS-based elastomeric particles using the bulk-emulsion
process is suitable for rapid proof-of-concept experimentation; however their use as
accurate and sensitive platforms for flow cytometry-based assays is problematic as a
result of the their large size distribution. Of several approaches evaluated for producing
monodisperse particles using Sylgard 184 all were successful but limited in the ability to
efficiently generate the large numbers of particles required for bioassay applications. A
potentially more robust alternate approach was to use a low molecular weight PDMS (1:1
ratio of prepolymer to crosslinking agent), with a viscosity of 450 cSt, in conjunction
with PDMS-based microfluidic systems (e.g., T-junction and flow focusing
configurations) and a biocompatible surfactant (Pluronic® F108). Such an approach
demonstrated the synthesis of ~400 monodisperse elastomeric particles per second for ~
10 consecutive hours.
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Particles Biofunctionalized and Used in Flow Cytometry-based Assays
Elastomeric particles that were synthesized from Sylgard 184 (specific gravity ~
1.03) or low molecular weight PDMS (specific gravity ~ 0.97) in the absence of
surfactant (CTAB, tween 20) were shown to be easily functionalized using non-specific
adsorption of avidin or streptavidin protein. Avidin adsorbed onto the hydrophobic
surface of polydisperse elastomeric particles (Sylgard 184) was shown to specifically
bind biotin-4-fluorescein after elastomeric particles were blocked with a BSA protein;
thus demonstrating biotin-binding functionality and minimal denaturation of the bound
avidin protein.
Polydisperse elastomeric capture microparticles (ECµPs -synthesized from
Sylgard 184) with a biotinylated human prostate specific antigen (PSA) monoclonal
antibody were shown to be capable of capturing human PSA with a high signal-to-noise
ratio in high protein content backgrounds (e.g., buffers with up to 10% human plasma
and 1mg/mL BSA ) and in small volumes with large amounts of protein (~20 µL of 1X
PBS with 1 mg/mL BSA). The results also demonstrated that a homogeneous (no
washing) sandwich assay configuration in conjunction with flow cytometry analysis can
be used for high signal-to-noise ratio detection and quantification of PSA or IgGphycoerythrin-(PE) protein bound to appropriately functionalized ECµPs. It was also
shown that monodisperse ECµPs could be synthesized and functionalized for detection of
HDL. These results thus establish that ECµPs can be utilized in different homogeneous
assays that are detected and quantified using flow cytometry methods. Moreover, the
method for functionalizing these particles with avidin was easy and straightforward; it
also can allow the particles to be adapted to a wide variety of bioassays by taking
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advantage of the many different biotinylated biomolecules that are commercially
available.
The next logical step for future development will be methods for scaled up
production and functionalization of monodisperse ECµPs. A potentially promising
approach outlined above involves synthesis from low molecular weight PDMS using
PDMS-based microfluidic systems (T-junction or flow focusing configuration).
Functionalization of these monodisperse ECµPs could be achieved by incorporating a
biotinylated Pluronic® F108 surfactant in the production process.1 Once monodisperse
elastomeric particles are thermally-crosslinked, and assuming that the biotin moiety
maintains proper orientation without significant denaturation, they can be further
functionalized using avidin and biotinylated-antibody (e.g., biotinylated-HDL
monoclonal). Because of their more uniform size monodisperse ECµPs can allow more
accurate use of fluorescence intensity as a basis for quantification of bound analyte. With
appropriate calibration methods (e.g., standard curves generated using ECµPs incubated
with a range of known analyte concentrations) monodisperse ECµPs offer an attractive
novel approach for rapid detection and quantification of clinically important analytes
circulating in blood and other fluids. .

141

Acoustic Focusing and Separation
Polydisperse elastomeric particles synthesized from Sylgard 184 and low
molecular weight PDMS function as negative acoustic contrast particles and can be
separated from positive acoustic contrast particles (blood cells and polystyrene) under the
application of an acoustic standing wave field within an acoustofluidic device (siliconbased and square glass microcapillary devices).
Acoustic separation of elastomeric particles (Sylgard 184) from a 0.1% porcine
(pig) blood sample, using a silicon-based acoustofluidic device with a downstream
trifurcation for collection and subsequent flow cytometry analysis, demonstrated a 9596% separation efficiency. Still, as we are using polydisperse ECµPs that vary in size
from many microns in diameter to those that are only hundreds of nm in diameter, it begs
the question of what separation efficiency is, as many ECµPs might be expected to
separate simply based on their size (inertial focusing)2 – without any relation to the
principle of negative acoustic contrast. In fact such inertial focusing may contribute to
the non-uniformity (i.e., apparent aggregation) of polydisperse ECµPs at the anti-nodes
of an acoustic field under flow conditions observed above. However, data reported in
this dissertation represent compelling proof of concept to support the conclusion that
ECµPs can be efficiently separated and collected away from blood cells within a mixture
using acoustophoresis. Future separation efficiency experiments using monodisperse
ECµPs will allow a more precise quantification of the separation efficiency.
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ECµPs (Sylgard 184) were successfully used in IgG-PE capturing in a diluted
whole porcine blood sample (0.1% blood diluted in 1X PBS with 0.1% BSA) followed by
acoustophoresis and flow cytometry analysis. The ability to detect an IgG biomolecule at
a 21 pM concentration (~ 3 ng/mL) in a blood-based sample with a high protein content
background (1X PBS with 0.1% BSA) demonstrates the potential of using ECµPs in
medically-relevant bioassays (e.g., plasma, blood). Furthermore, the use of
acoustophoresis to separate ligand-bound ECµPs prior to performing the assay, has
potential to obviate the need of time-consuming preparation steps (e.g., red blood cell
removal via centrifugation or lysis steps) that may cause non-specific loss of desired
biomarkers leading to a reduction in the accuracy of the reported results. As a result of
the continuous separation and collection of ligand-bound ECµPs using acoustophoresis,
methods can be developed to allow a continuous feed of separated ligand-bound ECµPs
into a flow cytometer for increased analysis rates. The use of lab-on-chip technology
may also allow for rapid separation and analysis of separated and concentrated ECµPs
using a low-cost flow cytometry set-up.3,4
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